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1. INTRODUCTION
Genome contains a huge set of genes, which all do something and do it at the 
right time in the right place. They all depend on each other and their activities 
are often regulated by each other. They form a large network, all components of 
which exist in the balance. But sometimes something goes wrong and some 
components of the machinery are not controlled any more. Therefore, cells 
have developed various systems for repair of different abnormalities. One 
possible output of uncontrolled life of cells is development of cancer. To 
prevent this fate, cells have tumor suppressor genes, primary role of which is to 
protect them from abnormal proliferation.
Tumor suppressor p53 is a very prominent protein: it does almost everything 
and nothing at the same time. It is involved in regulation of cell cycle and 
apoptosis, activates and represses transcription, is involved in DNA replication 
and repair, binds DNA and sometimes degrades it, represses translation of some 
mRNAs, reanneals single-stranded nucleic acids and has a protease activity, but 
in spite for all that, it is not necessary for normal life of cells. The only real 
function of p53 seems to be tumor suppressing, which is needed for prevention 
of cancer development. Due to its unique role, p53 is very attractive target in 
cancer therapy and much effort has been made for restoration its activity in 
cancer cells. Its crucial role in cancer development and numerous activities 
have also made p53 one of the most intensively studied proteins during past 
years.
In August 1998, the Medline database contained over 6700 records, which 
had a word “p53” in the Title of the document. The experimental part of this 
thesis is based on three of them, which all discuss activation of transcription by 
p53. The first two papers describe ability of p53 to inhibit its own trans- 
activating activity at high protein concentrations and the structural require­
ments for that. Results of the third paper suggest that p53 needs an essential 
cofactor to be fully active transactivator.
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2. REVIEW OF LITERATURE
2.1. p53 protein
2.1.1. p53 and tumorigenesis
After its discovery in 1979 (Lane and Crawford, 1979; Linzer and Levine, 
1979) p53 has been one of the most extensively studied proteins. The early 
observations that p53 is frequently overexpressed in tumor cells, regardless of 
the transforming agent and the cell type, were the basis for the concept that this 
protein can serve as a general marker for tumor cells (Rotter, 1983). Later 
investigations revealed that actually a mutated p53 is overexpressed in tumors, 
while wt protein is expressed in normal cells at very low level. Further studies 
indicated that wt p53 has a growth suppressing property and expression of wt 
p53 prevents cell transformation with many viral and cellular oncogenes 
(Eliyahu et al., 1989; Finlay et al., 1989; Baker et al., 1990). Therefore, p53 
was defined as a tumor suppressor gene.
The idea, that p53s primary role is to act as tumor suppressor, was further 
supported by establishment of p53 knockout mice. The initial result of analysis 
of p53~/_ mice was that they develop normally, but are highly susceptible to 
spontaneous formation of tumors (Donehower et al., 1992). Later studies, 
however, indicated that 8-16% of the p53-deficient embryos developed abnor­
mally. In some cases, defects in neural tube development, such as exencephaly, 
were observed (Sah et al., 1995). In agreement with the notion that p53 is a 
tumor suppressor gene, p53~/_ mice developed a high frequency of tumors, 
mainly lymphomas, at an early age. However, the particular genetic background 
of the mice affects tumor incidence and spectrum. Mice heterozygous for 
inactivated p53 allele also show increased incidence of spontaneous malignan­
cies as compared to p53+/+ mice. In this case, the heterozygous mice develop 
predominately osteosarcomas and soft tissue sarcomas. In the majority of cases 
with heterozygotes, the wt p53 allele has been lost in tumors (Donehower et al., 
1992; Harvey et al., 1993; Jacks et al., 1994; Purdie et al., 1994).
It is now well anticipated that the inactivation of wild type p53 is a key 
event in tumorigenesis. The best studied way of p53 inactivation is by mutating 
its gene. Indeed, p53 mutations are found in about 50-55% of all human 
cancers (Hollstein et al., 1994). Approximately half of the major forms of 
cancer contain p53 missense mutations, about 40% of which localize to certain 
“hot spots” along the p53 molecule (Fig. 1). Humans, who are heterozygous for 
the wild-type allele of p53, develop cancer with a very high frequency (greater 
than 90-95%) and often at early age.
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Figure 1. Structure of p53 protein and location of different functional domains. The 
three-dimensional structures of the DNA-binding domain complexed with 
DNA (Cho et al., 1994) and tetramerization domain (Lee et al., 1994) are 
shown as ribbon diagrams of the backbone of the protein, ß-strands are 
shown as arrows and a-helices as coils. The five conserved regions of the 
protein are indicated in roman numerals. The frequency of tumor-derived 
mutations at each residue (Cariello et al., 1994) is plotted as histogram along 
the top.
Less studied, but probably not less important than mutations in p53 gene is the 
functional inactivation of p53. Some tumors, containing wt p53, have amplified 
mdm2 gene, product of which leads to inactivation of transactivation activity of 
p53 and also causes rapid degradation of p53 (Oliner et al., 1992; Reifenberger 
et al., 1993). The second known mechanism leading to inactivation of wt p53 is 
its sequestration into the cytoplasm, which was first described in breast cancer 
cells and subsequently in undifferentiated neuroblastomas (Moll et al., 1995). If 
we add other, yet unidentified, ways of inactivation of p53 (or its pathway), it is 
very likely that disruption of p53 activity is necessary for developing most of 
the tumors.
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2.1.2. Structure of p53 protein
2.1.2.1. Functional domains
Human p53 protein contains 393 amino acid residues which can be divided at 
least into five functional domains (Fig. 1): the transactivation domain (residues 
1-40), the “proline-rich” domain (residues 60-90), the DNA-binding domain 
(residues 100-300), the oligomerization domain (residues 326-355) and the 
regulatory domain (residues 360-393).
The transactivation domain of p53 was first described in 1990 as a region of 
p53 which can activate transcription of reporter gene when fused with GAL4 
DNA binding domain (Fields and Jang, 1990; Raycroft et al., 1990). It contains 
many charged amino acid residues and is responsible for interactions with 
general transcription factors. One of the five evolutionary conserved regions is 
located in the transactivation domain (Soussi and May, 1996). This region 
(residues 12-23 of human p53) is implicated in interaction with mdm2 protein 
(Marston et al., 1994; Picksley et al., 1994). The latter negatively regulates p53 
activity and is probably the main cellular switch which “turns o ff’ p53 when 
p53 signalling pathway is not necessary any more.
The proline-rich domain was most recently defined as an autonomous 
functional region which is necessary for efficient growth suppression and 
receiving the antiproliferative signal initiated by Gasl protein (Walker and 
Levine, 1996; Ruaro et al., 1997). It contains five repeats of the amino acid 
sequence PXXP (P designating proline and X designating any amino acid). This 
motif is characteristic for interactions with proteins containing the SH3 domain 
and therefore can be a docking site of different factors which in turn can induce 
or suppress p53 activities. This region of the protein seems to be also involved 
in induction of apoptosis by p53 (Sakamuro et al., 1997; Venot et al., 1998) 
and is necessary for inhibition of papillomavirus replication (Lepik et al., 
1998). Recent studies indicate that a part of this region (residues 80-93) is 
implicated in regulation of the sequence-specific DNA binding of p53 (Hansen 
et al., 1998; Müller-Tiemann et al., 1998).
The central part of p53 (amino acid residues 100-300, named also “the core 
domain”) is the sequence specific DNA binding domain (Bargonetti et al., 
1993; Halazonetis and Kandil, 1993; Pavletich et al., 1993; Wang et al., 1993). 
This region contains four of five evolutionary conserved domains of p53 and is 
the most frequently mutated region of p53 found in tumor cells. In addition to 
direct contact with DNA this domain plays crucial role in formation of overall 
conformation of the protein. Three-dimensional co-crystal structure of the DNA 
binding domain bound to its cognate site has been determined (Fig. 1; Cho et 
al., 1994). The domain consists of a ß sandwich, comprising two antiparallel ß 
sheets, that serves as a scaffold for the structural elements at the DNA-protein 
interface. There are two components of these structural elements: a loop-sheet- 
helix motif that binds in the major groove and is involved in contacts with the
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bases, and two large loops (L2 and L3) that interact so that a critical residue, 
Arg248 (in L3), makes contact with the minor groove of DNA in the A/T-rich 
region of the binding site. L2 and L3 interactions are stabilized by the zinc 
atom held in place by four metal-binding ligands, Cysl76 and His 179, which 
are in the L2 loop, and Cys238 and Cys242, within the L3 loop. Importantly, 
four evolutionary conserved regions comprise the L2 and L3 loops and the 
loop-sheet-helix motif that have critical roles in providing the structure, 
surfaces and residues that actually contact DNA. Based on crystal structure 
data, there are two major classes of naturally occurring mutations in p53: 
mutations in residues directly contacting DNA and those that disrupt the 
structural integrity of the domain. In both cases, p53 is not able bind to DNA, 
demonstrating that sequence-specific DNA binding is central to the normal 
functioning of p53 as a tumor suppressor.
The oligomerization domain is necessary to form p53 homo di- and tetram- 
ers. Although monomeric p53 retains some of wt protein activities (partial 
growth suppressor activity, activation of transcription form certain promoters, 
sequence-specific DNA binding to some binding sites), the tetrameric confor­
mation of p53 is necessary to achieve fully functional protein (Shaulian et al., 
1993; Crook et al., 1994; Sang et al., 1994; Pellegata et al., 1995). In cells het­
erozygous for p53 the heterooligomerization of mutated p53 with wt protein is 
the main way to inactivate the wt protein. Oligomerization domain of human 
p53 has been mapped between residues 326-355 (Wang et al., 1994), three- 
dimensional structure of this fragment has been determined using nuclear 
magnetic resonance (Fig. 1; Lee et al., 1994) and X-ray crystallography (Jeffrey 
et al., 1995). Each p53 monomer is comprised of a ß-strand (residues 326-333), 
a tight turn (Gly334) and a a-helix (residues 335-354). Consistent with its role 
as a critical hinge residue between the ß strand and the a  helix, Gly334 is 
conserved across the species (Soussi and May, 1996) and is one of the few 
oligomerization domain residues that has been found to be mutated in tumors 
(Greenblatt et al., 1994). The tetramer can be described as a dimer of dimers, 
each primary dimer of which is formed by an antiparallel ß-sheet and two anti­
parallel a-helices. Two of these dimers associate across second and distinct 
parallel helix-helix interface to form tetramer. The ß strands are on the outside 
of tetramer and are not involved in dimer-dimer interactions.
The last 30 С-terminal amino acids of p53 are defined as a region which 
regulates sequence-specific DNA binding activity of the core domain. Under 
normal circumstances the p53 is in the “latent” form: its sequence-specific 
DNA binding activity is down-regulated. Modification of С-terminal domain 
removes the inhibitory effect from the core domain and sequence-specific DNA 
binding of the protein is activated. Activating modifications can be phospho­
rylation by casein kinase II or protein kinase С (Hupp et al., 1992; Takenaka et 
al., 1995), acetylation (Gu and Roeder, 1997) or glycosylation of C-terminus 
(Shaw et al., 1996). DNA binding of p53 can be activated also by binding of
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antibody рАЬ421 to the C-terminus or with deletion of the last 30 amino acids 
of the protein (Hupp et al., 1992). Importantly, the carboxy-terminal domain of 
p53 recognizes certain types of damaged DNA including short single-stranded 
DNA molecules which also activate the sequence-specific DNA binding 
function of p53 (Bakalkin et al., 1995; Jayaraman and Prives, 1995; Lee et al., 
1995; Reed et al., 1995). Therefore the C-terminus can be a sensor which 
receives signal of DNA damage and responses to it by activating sequence- 
specific DNA binding of p53. One possible switch from the latent to the active 
state of p53 is induction of alternative splicing of p53 transcript. Alternatively 
spliced mRNA has been described in mice cells and it encodes p53 protein 
which is 9 amino acids shorter and has 17 different amino acids at the carboxyl 
terminus compared to “regularly spliced” form (Arai et al., 1986; Kulesz- 
Martin et al., 1994). This protein is permanently active for DNA binding (Wu 
et al., 1994; Wolkowicz et al., 1995).
2.1.2.2. Conformational flexibility
Although structures of the DNA binding and oligomerization domains of p53 
are determined, the conformation of the whole molecule is not known. Little is 
known about the conformation of transactivation and proline-rich domains in 
the N-terminus and also about the linker region between DNA binding and 
oligomerization domains. The structure and intramolecular interactions of the 
С-terminal domain have been not determined either, but there is strong evi­
dence that at least some parts of the molecule are capable of change their 
conformations. First, the С-terminal domain inhibits the sequence-specific 
DNA binding activity of the core domain and this inhibition is “removable” by 
many factors. Second, p53 has epitopes for some antibodies that can be accessi­
ble in certain cases but not in the other cases.
The conformational stages of p53 protein are mostly described by interac­
tions with different antibodies. p53 reactive to pAb240 antibody is defined as a 
“mutant” conformation, because most of the mutated p53s have this epitope 
exposed. The “wild-type” conformation does not bind to pAb240, but reacts 
with pAbl620 and pAb246 antibodies. It has been proposed that wt p53 protein 
can switch between both conformations and this flexibility could be prerequi­
site for interacting with DNA. On the other hand, mutant p53s are locked into 
“mutant” conformation and have therefore lost its DNA binding activity 
(Milner, 1995). According to this model, it has been shown that wt p53 adopts 
“mutant-like” conformation when bound to DNA (Halazonetis et al., 1993; 
Halazonetis and Kandil, 1993). As the DNA binding domain of p53 contains a 
zinc atom which interacts with L2 and L3 loops and stabilizes conformation of 
the core domain (Cho et al., 1994), the “mutant” conformation of wt protein 
can be also induced by chelation of zinc or increasing concentration of copper 
(Hainaut et al., 1995; Verhaegh et al., 1997; Verhaegh et al., 1998). The latter
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probably competes with zinc in binding to p53 and disrupts the exact structure 
of the core domain.
2.1.3. Activities of p53
Very intensive studies of p53 during past years have revealed that many 
processes in the cell are directly or indirectly influenced by p53. This can re­
flect a central role of p53 in the regulation of cell life, but on the other hand, it 
is hard to imagine that one molecule can posses so many activities at the same 
time. At least some of the following activities have been tested in vitro only, 
therefore their relevance in vivo remains unclear. However, despite its many 
functions and important role in cancerogenesis, p53 is not essential protein in 
development, because at least some p53_/~ mice develop and live normally — 
until they die due to tumors (Donehower et al., 1992). This indicates that p53 is 
first of all needed for blocking the unregulated proliferation of cells.
The most pronounced property of p53 is acting as transcriptional regulator. 
It activates transcription of many genes, several of which are involved in 
mediation of p53-dependent cell cycle block in Gi or G2 phase. G| block is 
mostly achieved by activation of transcription of W afl, a inhibitor of Gi cyclin- 
dependent kinases (El-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 
1993a). G2 block can be mediated, at least in some cell types, by activation of 
transcription of 14-З-За gene (Hermeking et al., 1997). p53 also represses 
transcription from many cellular and viral promoters. The biological meaning 
of repression is unclear, but the ability of p53 to repress transcription correlates 
with its ability to induce apoptosis.
p53 induces apoptosis in some cell types. It is not clear whether transcrip­
tional activation property of p53 is needed for this activity, but most probably 
both transcription dependent and independent mechanisms are involved in the 
induction of apoptosis. At least in some cells, transactivation competent p53 is 
more powerful inducer of apoptosis than its transactivation incompetent mu­
tant. Genes like Bax and IGF-BP3, products of which influence the progression 
of apoptosis, are potential transcriptional targets of p53 (Buckbinder et al., 
1995; Miyashita and Reed, 1995). On the other hand, it is quite difficult to 
evaluate the role of p53 in induction of these genes as compared to other factors 
accompanying the ongoing of apoptosis. Clearly, p53 is not the only factor 
which regulates their transcription.
p53 inhibits both cellular and viral replication in in vitro and in vivo assays. 
In some circumstances the direct and indirect (through induction of cell cycle 
arrest or apoptosis) mechanisms of inhibition of replication are indistinguish­
able, but some recent works indicate that neither the cell cycle arrest nor 
apoptosis is responsible for this activity. Neither is the activation of transcrip­
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tion by p53 involved, because p53 inhibits cellular DNA replication in tran­
scription free Xenopus egg extracts in vitro and transactivation incompetent 
mutant of p53 inhibits papillomavirus replication in vivo (Cox et al., 1995; 
Lepik et al., 1998).
The loss of wt p53 activity contributes to genomic DNA amplification, 
indicating possible role of p53 in the control of genome integrity (Livingstone 
et al., 1992; Yin et al., 1992). p53 interacts with DNA repair (and transcription) 
factor TFIIH, down-regulating its helicase activity, and with Rad51 protein, 
which is involved in DNA recombination (Wang et al., 1995a; Leveillard et al., 
1996; Stürzbecher et al., 1996). Also, p53 can catalyze reannealing of single­
stranded complementary nucleic acids in vitro (Oberosler et al., 1993; Bakalkin 
et al., 1994). Based on these facts it has been proposed that p53 could be 
directly involved in DNA repair and recombination processes.
It has been reported that p53 can repress translation of at least two mRNAs: 
its own and CDK4 mRNA (Ewen et al., 1995; Mosner et al., 1995). Repression 
of its own mRNA can be involved in keeping the p53 protein in the low level 
and its induction after DNA damage, repression of CDK4 translation may be 
involved in regulation of cell cycle by p53.
There have been two additional enzymatic activities of p53 described: 
1) p53 possesses intrinsic 3’—>5’ exonuclease activity in vitro (Mummenbrauer 
et al., 1996), which can be involved in regulation of DNA repair or replication 
by p53. 2) p53 is a autoprotease that can cleave itself from both N- and C-termi­
nus and this can be involved in regulation of DNA binding, transactivation or 
other activities of p53 (Molinari et al., 1996; Okorokov et al., 1997).
2.2. p53 as a modulator of transcription
2.2.1. Interactions with general transcription machinery
Transcriptional activation by p53 is based on its ability to bind sequence-spe- 
cifically to DNA and recruit the general transcription factors to the promoters 
located near to its binding site. TATA-box binding protein (TBP) was the first 
identified protein among the general transcription factors which interact with 
p53 (Seto et al., 1992; Liu et al., 1993; Martin et al., 1993; Truant et al., 1993). 
The TBP binding domain on p53 was mapped to transactivating domain (Liu et 
al., 1993), later studies revealed that the second TBP binding site is located in 
the C-terminus of p53 (Horikoshi et al., 1995). TBP is capable of interacting 
with p53 also when bound to its cognate DNA site (Martin et al., 1993) and p53 
also cooperates with either TBP or TFIlD when binding to DNA fragment 
containing both TATA-box and p53 binding site (Chen et al., 1993). Although 
direct interaction between TBP and p53 has been well documented, there is a 
doubt about the physiological relevance of this interaction: 1) p53 double
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mutant at amino acids Leu22 and Trp23 is not able to activate transcription, 
although it retains nearly full TBP binding activity (Lin et al., 1994). 2) Muta­
tions in TBP, which disrupt its association with p53 in vitro, do not disrupt its 
transcriptional response to p53 activation domain in vivo (Tansey and Herr,
1995). It is more likely that the true target of p53 is the entire TFIID complex, 
consisting of TBP and associated factors, in which the interaction with TBP is 
possible but not critical for transactivation. Indeed, p53 interacts also with 
TBP-associated factors, TAFn40 and TAFn60, from Drosophila cells and 
TAFn31 from human cells and these interactions are disrupted by mutations at 
amino acids 22 and 23 in p53 protein (Lu and Levine, 1995; Thut et al., 1995).
p53 interacts also with components of TFIIH complex: ERCC2 (XPD), 
ERCC3 (XPB) and p62 (Xiao et al., 1994; Wang et al., 1995a; Leveillard et al.,
1996). Both N and С termini of p53 are involved in these interactions. TFIIH is 
multifunctional complex which is involved in initiation of transcription, in cell 
cycle regulation and in DNA repair (Seroz et al., 1995). The complex has two 
enzymatic activities: ERCC2 and ERCC3 are helicases that are essential 
components of the cellular DNA repair machinery (Schaeffer et al., 1993; 
Schaeffer et al., 1994), and the kinase complex CAK (CDK-activating kinase) 
phosphorylates С-terminal domain of RNA Pol П large subunit and may 
thereby regulate initiation and elongation of transcription (Lu et al., 1992). 
Functional meaning of p53-TFIIH interaction is unclear in respect to both 
transcriptional regulation and regulation of TFIIH-mediated nucleotide excision 
repair (NER). It has been shown that p53 does not affect NER in vitro 
(Leveillard et al., 1996), although it inhibits activity of both helicases of the 
TFIIH complex (Wang et al., 1995a; Leveillard et al., 1996). Two recent 
studies propose that TFIIH-p53 interaction can be important first of all for 
regulation of p53 itself. TFIIH associated kinase complex CAK (consisting 
from three subunits: CDK7, cyclin H and p36MAT1) also interacts with p53 and 
phosphorylates its N- or C-terminus (Ко et al., 1997; Lu et al., 1997). The 
functional relevance of these phosphorylations remains to be determined, but it 
has been proposed that phosphorylation of C-terminus by CAK activates 
sequence-specific DNA binding of p53 (Lu et al., 1997). However, TFIIH as a 
component of the DNA repair complex can be a upstream messenger that 
“informs” p53 about DNA damage.
In addition to interactions with the general transcription factors, p53 binds 
also cellular proteins p300 and СВР (Avantaggiati et al., 1997; Gu et al., 1997; 
Lill et al., 1997; Scolnick et al., 1997). Both proteins possess histone acetyl- 
transferase activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996). 
The acetylation of histones is thought to be involved in destabilization and 
restructuring of nucleosomes, which is likely a crucial event for accessibility of 
transcription factors to DNA templates. Therefore it is possible that the first 
step of activation of transcription by p53 is to bring histone acetyltransferases 
near to the particular promoter. After being relieved from histones, promoter is
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ready to bind basal transcription factors, TFIID for example. In accordance 
with this model, co-expression of СВР or p300 with p53 enhances p53-depend- 
ent activation of transcription (Avantaggiati et al., 1997; Gu et al., 1997). The 
binding site of СВР is mapped to transactivation domain of wt p53, mutations 
at residues Leu22 and Trp23 disrupt the interaction (Gu et al., 1997; Scolnick 
et al., 1997). The interaction between p300 and p53 has also importance for 
p53 activity: p300 acetylates p53 at the С-terminal regulatory domain, preferen­
tially at Lys373 and Lys382, which in turn leads to the activation of DNA bind­
ing of p53 (Gu and Roeder, 1997).
2.2.2. Interactions with DNA
p53 is able to bind DNA in two different ways: sequence-specifically and non- 
specifically. Sequence-specific binding is required first of all for transcriptional 
activation by p53, non-specific interaction is involved in activation of se­
quence-specific DNA binding, participates in recognition of damaged DNA and 
is needed for other activities (reannealing of nucleic acids, exonuclease activ­
ity). The core domain of p53 (amino acids 100-300) is responsible for se­
quence-specific DNA binding, whereas non-specific binding is intrinsic prop­
erty of both core and С-terminal regulatory domains.
p53 binds specifically 20 base pair DNA sequence containing two copies of 
motif 5’-PuPuPuC(A/T)(A/T)GPyPyPy-3’ separated by 0-13 bases (El-Deiry et 
al., 1992; Funk et al., 1992). Regardless to the fact that this sequence allows 
very broad variation, the natural p53 binding sites found in promoters of target 
genes do not meet the whole criteria for this consensus. There is at least one 
mismatch in every real binding site (Table 1). On the other hand, sometimes 
there are two p53 binding sites in the vicinity of target gene promoter, which 
can compensate deficiency of each individual site. Moreover, not all sequences, 
which perfectly match with consensus, are bound by p53 in vitro (Halazonetis 
et al., 1993). All these circumstances (including variation of space between two 
decamers in the consensus) make it very difficult to predict the real functional 
p53 binding sites. It is estimated that the human genome could contain approxi­
mately 200-300 of such sites (Tokino et al., 1994).
The consensus site can be viewed as a structure of four quarter-site repeats: 
5’-PuPuPuC(A/T)-3’ considering that the rest of a half site [5’-(A/T)GPyPyPy- 
3’] forms the same sequence on the complementary strand of DNA. Each pen- 
tameric repeat binds to single monomer of tetrameric p53 protein. Monomeric 
p53 molecules, which have lost their oligomerization capacity, bind to the 
consensus site as four monomers only, indicating that this binding is strongly 
cooperative (Balagurumoorthy et al., 1995; Wang et al., 1995b). Binding of 
p53 to DNA causes considerable bending of DNA chain. The bending angle
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varies between different sites, but is greater (up to 50°) in high affinity sites. In 
particular, response elements having a CATG sequence at the junction of two 
consensus pentamers in each half-site favor highly bent complexes, whereas 
response elements having CTTG bases at this position are less bent (Nagaich et 
al., 1997).
Sequence-nonspecific DNA binding through the С-terminal domain of p53 
has several implications. When bound to short single-stranded DNA, the C-ter- 
minal domain “rescues” the sequence-specific DNA binding activity of the core 
domain (Jayaraman and Prives, 1995). One explanation of this activation is that 
p53 is tightly bound to cellular DNA through its С-terminal domain and short 
ssDNA releases p53 by competing for binding to С-terminal domain. When 
bound to ssDNA, p53 is “relatively free” to move and make interactions 
through the core domain. According to this model, it has been shown that large 
DNA molecules actually inhibit intrinsic sequence-specific DNA binding 
activity of purified p53, whereas short DNA molecules can overcome this
Table 1. Genomic p53 binding sites. Capital letters indicate bases matching with the 
consensus, bold letters indicate mismatches, letters in italics indicate spacer 
sequence between consensus decamers.
Name Sequence Reference
Consensus PuPuPuC(A/r)(A/T)GPyPyPyM,.oPuPuPuC(A/T)(A/T)GPyPyPy (El-Deiry et al., 
1992)
W afl
(human)
GAACATGTCC cAACATGTTg (El-Deiry et al., 
1993)
Mdm2 (1)
(mouse) (2)
GGtCAAGTTg GGACAcGTCC 
AGctAAGTCC tGACATGTCT
(Juven et al., 
1993; Wu et al., 
1993)
Mdm2 (1)
(human) (2)
GGtCAAGTTC AGACAcGTCC 
GAttAAGTCC tGACTTGTCT
(Zauberman 
et al., 1995a)
GADD45
(human)
GAACATGTCT AAGCATGCTg (Kastan et al., 
1992)
Cyclin G
(mouse)
AGACcTGCCC GGGCAAGCCT (Okamoto and 
Beach, 1994)
Cyclin G (1)
(rat) (2)
AGACcTGCCC GGGCAAGCCT 
AcGCAAGCCC GGGCTAGTCT
(Zauberman 
etal., 1995b)
MKC
(mouse)
tGGCAAGCCT A tGACATGgCC (Zambetti et al., 
1992)
Bax
(human)
tcACAAGTTa G AGACAAGCCT (Miyashita and 
Reed, 1995)
PCNA
(human)
AcAtATGCCC GGACTTGTTC (Shivakumar 
et al., 1995)
RGC
(human)
GGACTTGCCT GGcCTTGCCT (Kern et al., 
1991)
IGF-BP3
(human) boxA 
boxB
AAACAAGCCa С cAACATGCTT 
GGGCAAGaCC tGcCAAGCCT
(Buckbinder 
etal., 1995)
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inhibition (Anderson et al., 1997). This type of p53 activation can occur in cells 
during excision repair after UV-dependent DNA damage: the human excinucle- 
ase complex first recognizes UV damaged DNA and then introduces single 
strand incisions at positions 3’ and 5’ to the mismatch. A product of the subse­
quent repair of the lesion is the release of single-stranded 29-mer DNA (Huang 
et al., 1992), which is a good candidate for activating p53. Another function of 
DNA binding by С-terminal domain is that it specifically recognizes and binds 
to some types of damaged DNA. p53 (and its С-terminal domain) binds to 
insertion/deletion mismatches in double-stranded DNA (Lee et al., 1995), to the 
ends of single-stranded DNA (Bakalkin et al., 1994; Bakalkin et al., 1995; 
Selivanova et al., 1996), and to DNA damages introduced enzymatically 
(Dnase I, produces mostly single-stranded nicks) or by ionizing radiation 
(causes variety of strand breaks; Reed et al., 1995). These interactions may be 
involved in activation of sequence-specific DNA binding or stability of p53. 
p53 also possesses activity of reannealing complementary nucleic acids. Non­
specific DNA binding by the С-terminal domain of the protein is needed for 
this activity (Oberosler et al., 1993; Bakalkin et al., 1994; Bakalkin et al., 1995; 
Wu et al., 1995).
2.2.3. Target genes
Several target genes directly activated by p53 have been identified. These in­
clude muscle creatine kinase (Zambetti et al., 1992), Mdm2 (Barak et al.,
1993), WAF1 (El-Deiry et al., 1993), GADD45 (Kastan et al., 1992), cyclin G 
(Okamoto and Beach, 1994), Bax (Miyashita and Reed, 1995), IGF-BP3 
(Buckbinder et al., 1995), “PIG group” genes (Polyak et al., 1997), 14-3-3a 
(Hermeking et al., 1997) and others. Although p53 can activate transcription of 
these genes, they also have p53-independent ways for regulation of their 
expression. There are clear biological outputs associated with induction of 
some p53 responsive genes, whereas the relevance of others remains obscure.
2.2.З.1. Genes associated with cell cycle regulation.
Wafl (also named p21 or Cipl) is the best studied p53 response gene. The 
protein encoded by this gene forms part of a quaternary complex with cy- 
clin/CDKs and the DNA polymerase processivity factor PCNA found in normal 
cells (Xiong et al., 1993b). At high protein concentrations, Wafl inhibits the 
function of CDKs, particularly of those which function during the Gi phase of 
the cell cycle (Harper et al., 1993; Xiong et al., 1993a). In response to irradia­
tion, p53-dependent Gi arrest is mediated, at least in part, through the induction 
of Wafl by p53 (El-Deiry et al., 1994). At this point p53 pathway meets
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another tumor suppressor gene: Rb. Inhibition of CDKs leads to the accumula­
tion of hypophosphorylated Rb which binds (and therefore inactivates) E2F 
family transcription factors. E2F in turn activates number of genes required to 
initiate or propagate the S phase of the cell cycle. Wafl has also been impli­
cated in regulating DNA replication. Wafl directly interacts with PCNA and 
inhibits PCNA-dependent DNA replication (but not DNA repair synthesis) in in 
vitro systems (Flores-Rozas et al., 1994; Li et al., 1994; Waga et al., 1994). 
Therefore, Wafl may block chain elongation during DNA synthesis through its 
interaction with PCNA while permitting PCNA-dependent nucleotide excision 
repair to occur. However, cells derived from Wafl null mice retain some ability 
to arrest in Gj in response to DNA damage (Brugarolas et al., 1995; Deng et al.,
1995), indicating that Wafl is not entirely responsive for antiproliferative effect 
of p53. The DNA sequence in Wafl gene responsible for binding p53 is located 
2.4 kb upstream of TATA box (El-Deiry et al., 1993).
GADD (growth arrest and DNA damage) genes were initially isolated on the 
basis of their induction after DNA damage in mammalian cells (Fornace et al., 
1988; Fornace et al., 1989). GADD45 gene is induced after DNA damage in 
many types of cells in p53 dependent manner (Kastan et al., 1992). The 
GADD45 protein was reported to interact with the PCNA and to inhibit the 
entry of cells into S phase of cell cycle upon re-stimulation with serum (Smith 
et al., 1994). Overexpression of GADD45 protein also results in the inhibition 
of colony formation (Zhan et al., 1994). p53 binding site is located in the third 
intron of GADD45 gene (Kastan et al., 1992). p53 contributes to activation of 
GADD45 gene even in absence of direct binding to DNA. In this case, the WT1 
binding site in front of GADD45 gene is required and p53 activation effect is 
achieved by interaction with WT1 protein (Zhan etal., 1998).
Cyclin G gene is strongly induced in p53-dependent manner after DNA 
damage (Okamoto and Beach, 1994; Zauberman et al., 1995b). The function of 
the protein is unknown, therefore its participation in the cell cycle regulation is 
hypothetical. Cyclin G has been shown to interact with B’ subunit of protein 
phosphatase 2A (Okamoto et al., 1996). p53 binding site was found 1.5 kb up­
stream of the coding sequence of mouse cyclin G gene (Okamoto and Beach,
1994). Rat cyclin G gene contains two p53 binding sites: 250 nucleotides 
upstream of transcriptional start site and in the first intron (Zauberman et al., 
1995b).
14-З-За was recently identified as a p53 response gene (Hermeking et al., 
1997). Induction of 14-З-За can be one mechanism how p53 mediates cell 
cycle block in G2 phase. Overexpression of the 14-3-3o causes the block of 
cell proliferation and accumulation of cells in G2/M phase. The possible 
mechanism of 14-3-3a in cell cycle regulation is that it binds to Cdc25C 
phosphatase, blocks its entry into cell nucleus and therefore abolishes dephos­
phorylation of Cdc2, a cyclin-dependent kinase required for entry into mitosis
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(Peng et al., 1997). A functional p53 biding site is located 1.8 kb upstream of 
transcription initiation site of 14-3-3a gene (Hermeking et al., 1997).
2.2.3.2. Genes associated with apoptosis
The Bax gene encodes a protein with homology to the survival factor Bcl-2. It 
is able to homodimerize and to form heterodimers with Bcl-2 protein. Site- 
directed mutagenesis of Bcl-2 protein indicated that Bcl-2 must bind to Bax 
protein to exert its apoptosis-suppressing activity (Yin et al., 1994). On the 
other hand Bax homodimers are potent inducers of apoptosis. Therefore relative 
levels of these two proteins may dictate whether a cell is susceptible to apopto­
sis (Oltvai et al., 1993). p53 activates transcription of Bax and therefore in­
duces unbalance between levels of Bcl-2 and Bax proteins which in turn can be 
one component needed for the induction of apoptosis. Binding site for p53 is 
located 70 nucleotides upstream of TATA box of human Bax gene (Miyashita 
and Reed, 1995).
IGF-BP3 (insulin-like growth factor-binding protein-3) blocks the IGF 
mitotic signalling pathway by binding to IGF and preventing its interaction with 
its receptor. Thus, blocking of IGF activity could enhance apoptosis or lower 
the mitogenic response of cells. There are three p53 binding sites in the IGF- 
BP3 gene: in intron 1 (Box A) and in intron 2 (Box B; Buckbinder et al., 1995). 
The third functional binding element was found by computer analysis and is 
located 70 nucleotides upstream of TATA box. Functional significance of this 
site was also confirmed (Bourdon et al., 1997).
“PIG (p53-induced genes) group” genes were found to be induced during 
onset of p53-dependent apoptosis. 14 transcripts were found to be markedly 
increased, many of these genes were predicted to encode proteins that could 
generate or respond to oxidative stress (Polyak et al., 1997). From this group of 
genes the PIG3 transcript was studied more detail. PIG3 is a novel gene highly 
related to TED2, a plant NADPH oxidoreductase. Recent data show that the 
proline-rich region of p53 is necessary for activation of PIG3 gene (Venot et 
al., 1998). p53 responsive element able to bind p53 is located 308 nucleotides 
upstream of transcription start site.
p53-dependent activation of apoptosis-associated Fas/APO-1 and Kil- 
ler/DR5 genes has also been reported (Owen-Schaub et al., 1995; Wu et al., 
1997), but p53 response elements of these genes have not been identified. 
Therefore, there remains the possibility that these two genes are not direct 
targets of p53.
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2.2.3.3. Mdm2: keeping p53 under control
The mdm2 gene encodes a protein which complexes with p53 and inhibits its 
transcriptional activation ability (Momand et al., 1992; Oliner et al., 1993). The 
mdm2 gene itself is a transcriptional target of p53 and is activated in response 
to UV irradiation, thus implying an autoregulatory feedback loop between p53 
and mdm2 (Barak et al., 1993; Perry et al., 1993; Wu et al., 1993). Two pro­
moters of mdm2 gene were characterized: the first one is located upstream of 
the gene and is expressed constitutively, whereas the second one is present 
inside the first intron and is controlled by p53 through two adjacent p53 
binding sites (Juven et al., 1993; Wu et al., 1993; Barak et al., 1994; Zauber­
man et al., 1995a).
Fine mapping with short synthetic peptides revealed that the mdm2 binding 
site on p53 spans amino acids 18-23 (Picksley et al., 1994), which coincide 
with the first evolutionary conserved domain of p53 (Soussi and May, 1996). 
Residues Leul4, Phel9, Leu22 and Trp23 of p53 were identified by mutational 
approach as critical residues making contact with mdm2 (Lin et al., 1994). 
Residues Leu22 and Trp23 are also required for transcriptional activation and 
binding to TAFn31, demonstrating an overlap between the transactivation 
domain and the mdm2 binding domain of p53 (Lin et al., 1994; Lu and Levine,
1995). In 1996 the three-dimensional structure of a 109 amino acid residues 
long amino-terminal domain of Xenopus laevis mdm2 bound to the 15 amino 
acid residues long transactivation domain of p53 was determined (Kussie et al.,
1996). This revealed that mdm2 has a deep hydrophobic cleft on which the p53 
peptide binds as an amphipathic a-helix. Residues Phel9, Trp23 and Leu26 of 
p53 stabilize these hydrophobic interactions between p53 and mdm2 in this 
cleft.
The functional significance of mdm2-dependent inactivation of p53 was 
demonstrated when it was attempted to produce mdm2 knockout mice. The first 
result was that mdm2-null genotype leads to embryonic lethality. Mdm2+/~ het­
erozygote mice are viable, develop normally and are fertile but interbreeding of 
mdm2+/~ heterozygotes failed to result in offspring with the mdm2“/_ genotype. 
Crossing mdm2+/_ mice with p53+/~ or p53~/_ mice resulted progeny that were 
homozygous for both mdm2 and p53 null alleles. No mice were recovered that 
were null for mdm2 at wt or heterozygous p53 background (Jones et al., 1995; 
Montes de Oca Luna et al., 1995). These results demonstrate that primary 
developmental role of mdm2 is to negatively regulate wt p53 function. More 
detailed investigation of mdm2 inhibitory role on p53 revealed that when p53 is 
bound by mdm2, it is targeted for destruction by the ubiquitin-dependent pro- 
teosome pathway (Haupt et al., 1997; Kubbutat et al., 1997). Binding of mdm2 
to p53 is necessary but not sufficient for degradation of p53: deletion mutant of 
mdm2 interacting with p53 and inhibiting p53-induced cell cycle arrest but 
lacking the С-terminal part of protein, is not able to induce degradation of p53 
(Kubbutat et al., 1997). At the conditions of genotoxic stress the p53 activity is
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continuously needed, but this causes accumulation of mdm2, which in turn 
leads to the degradation of p53. Therefore it is reasonable to expect that mdm2- 
p53 interaction is somehow regulated. There are several potential phosphoryla­
tion sites nearby mdm2 binding site on p53. It has been shown that phospho­
rylation of p53 residue Serl5 weakens p53-mdm2 interaction and DNA damage 
induces p53 phosphorylation at this site (Shieh et al., 1997; Siliciano et al.,
1997). Therefore phosphorylation at Serl5 can be a mechanism causing the 
protection of p53 from mdm2-dependent degradation. However, recent in vitro 
data show that phosphorylation of both Seri5 and Ser37 are needed for disrup­
tion of mdm2-p53 interaction. p53-TFDD interaction is disrupted by single 
phosphorylation at Seri5, but double phosphorylation at Seri5 and Ser37 
restores TFilD binding activity of p53 (Pise-Masison et al., 1998). Very 
attractive candidate for phosphorylation of these sites is the DNA-dependent 
protein kinase (DNA-PK), which requires DNA double-strand breaks or other 
discontinuities in DNA for activity (Gottlieb and Jackson, 1993; Morozov et 
al., 1994). Indeed, p53 is substrate of DNA-PK in vitro (Lees-Miller et al., 
1990; Lees-Miller et al., 1992). Mdm2 is also substrate of DNA-PK and its 
phosphorylation by DNA-PK also prevents mdm2-p53 interaction (Mayo et al.,
1997). On the other hand, DNA-PK activity is not required for accumulation of 
p53, indicating that alternative pathway for regulation of p53-mdm2 interaction 
may exist (Rathmell et al., 1997).
2.2.4. Repression of transcription
In addition to the activation of transcription from some promoters, p53 is also 
potent repressor of others. Whereas the transcriptional activation by p53 needs 
the functional p53 binding site vicinity of the promoter, the repression seems 
not generally depend on any DNA sequences. This also makes it more difficult 
to determine whether the particular promoter is a direct target of p53 or is its 
repression simply a secondary effect of p53. As p53 mediates many processes 
in the cell, including cell cycle arrest and apoptosis, it is likely that some pro­
moters reported to be repressed by p53 are in fact sensitive for cell cycle 
progression or onset of apoptosis or are dependent on proteins which are influ­
enced by p53. In addition: thus far the ability of p53 to repress transcription 
correlates to its ability to induce apoptosis. Nevertheless, several promoters are 
down-regulated by wt p53. These include many viral promoters like SV40 IE 
promoter and enhancer, RSV-LTR, human CMV IE promoter, HIV-LTR, 
HTLV-Typel-LTR, HSV thymidine kinase promoter, HSV UL9 gene promoter 
and HPV 18 and HPV 16 LCR (Subler et al., 1992; Jackson et al., 1993; De- 
saintes et al., 1995). Also hepatitis В virus (HPV) enhancer is repressed by p53 
and in this case p53 binds sequence-specifically to the enhancer region.
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However, the proximal sequence of HPV enhancer, containing binding site for 
RFX1 and c-Abl complex, is required to convert p53 to transcriptional re­
pressor (Ori et al., 1998). Cellular genes repressed by p53 include Bcl-2 
(Miyashita et al., 1994), rat brain creatine kinase (Zhao et al., 1994), microtu­
bule associated protein 4 (Murphy et al., 1996), hsp70 (Agoff et al., 1993), Ets- 
1 and Ets-2 (Iotsova et al., 1996), c-Myc (Ragimov et al., 1993), DPI 
(Gopalkrishnan et al., 1998), H19 (Dugimont et al., 1998) and others. Earlier 
investigations suggested that p53 specifically represses TATA-mediated but not 
initiator-mediated transcription (Mack et al., 1993). More recent studies, how­
ever, show that also many TATA-less promoters, like Ets-1, Ets-2, H19 and 
DPI, are efficiently repressed by p53 (Iotsova et al., 1996; Dugimont et al., 
1998; Gopalkrishnan et al., 1998). It is also reported that some promoters 
directed by RNA polymerase III are repressed by p53 (Chesnokov et al., 1996; 
Cairns and White, 1998).
Although monomeric p53 is able to activate transcription, it is not able to 
repress promoters (Crook et al., 1994; Sang et al., 1994; Subler et al., 1994; 
Shaulian et al., 1995). It has been demonstrated that phosphorylation of p53 
from the casein kinase П site (Ser386 on mouse p53) is required for efficient 
repression of transcription (Hall et al., 1996). On the other hand, phosphoryla­
tion of the same site essentially increases stability of p53 tetramerization in 
vitro (Sakaguchi et al., 1997). Thus, it can be the same thing: p53 must be 
tetrameric to repress transcription. One proposed mechanism how p53 represses 
transcription is through squelching of transcription factors. This is based on 
fact that p53 unable to interact with components of TFIID complex is also 
unable to repress transcription (Chesnokov et al., 1996; Roemer and Mueller- 
Lantzsch, 1996).
2.3. Regulation of p53 activity
2.3.1.Post-translational modifications of p53
The N- and C-termini of p53 are post-translationally modified in multiple sites 
by phosphorylation, O-glycosylation and acetylation. The last two modifica­
tions were discovered relatively recently and in both cases the sequence- 
specific DNA binding of p53 is activated. Glycosylation of p53 prevents its 
binding to antibody pAb421 (Shaw et al., 1996) indicating that the site of this 
modification lies near to pAb421 epitope (residues 371-381). Acetylation of 
p53 occurs also in the same region: lysines 373 and 382 (but also lysines 370, 
372 and 381 in lesser extent) are acetylated in vitro. In the case of acetylation, 
the ability of p53 to bind to pAb421 is not affected (Gu and Roeder, 1997). 
Whether and how the modifications of this region are regulated (or can they 
occur simultaneously) is not clear. The problem is even more complex, because
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also serines 376 and 378 are phosphorylated by PKC (see below). It is possible 
that each of these modifications is induced in different occasions and by differ­
ent factors, but give the same result in respect of p53 activity. Nevertheless, all 
modifications of this region (and binding to antibody) stimulate the sequence- 
specific DNA binding of p53, indicating its role in regulation of p53. It is 
proposed that this part of p53 interacts with the core domain inhibiting its DNA 
binding activity. Modification of C-terminus disrupts this association and 
makes thus possible the sequence-specific interaction of p53 with DNA.
p53 is phosphorylated by various kinases and several studies have revealed 
how it can regulate activities of p53. The N-terminal region of p53 appeared to 
be the most extensively phosphorylated part of the protein and target for 
various kinases. Phosphorylation by Casein I-like kinase in vitro has been 
shown at Ser4, 6 and 9 of mouse p53 (Milne et al., 1992). Based on sequence 
homology, phosphorylation of human p53 on Ser6 and 9 by the same kinase can 
be predicted. DNA-PK phosphorylates serines 15 and 37 of human p53 (Lees- 
Miller et al., 1992). Serine 15 of p53 becomes phosphorylated following DNA 
damage induced by either ionizing or ultraviolet radiation and this phosphoryla­
tion leads to reduced interaction of p53 with its negative regulator, mdm2 
oncoprotein (Shieh et al., 1997; Siliciano et al., 1997). Therefore, phosphoryla­
tion of Seri5 (by DNA-PK or some other kinase with similar specificity) may 
induce transactivation activity of p53 and also lead to stabilization of the 
protein. JNK1, JNK2 and JNK3 kinases, activity of which is induced by UV 
radiation, can phosphorylate Ser34 of mouse p53 (Milne et al., 1995; Hu et al.,
1997). According to sequence homology, Ser37 of human p53 can be phos­
phorylated by these enzymes. A related kinase, MAP-kinase, was found to 
phosphorylate mouse p53 on the Thr73 and Thr83 (Milne et al., 1994), how­
ever, no homologs of these sites seem to be present in human p53. So far, no 
correlation is found between activity of p53 and its phosphorylation by MAP 
and JNK kinases.
The C-terminus of p53 is also phosphorylated by several kinases. Serine 315 
of human p53 is phosphorylated by Cdc2 (Bischoff et al., 1990; Stürzbecher et 
al., 1990). More detailed investigation indicated that cyclin B/Cdc2 and cyclin 
A/Cdc2 efficiently phosphorylate this site in vitro, whereas p53 was only 
poorly phosphorylated by cyclin D/CDK4 and cyclin E/CDK2 complexes. In 
addition, phosphorylation of Ser315 strongly increases the binding of p53 to the 
cognate consensus sequence which is present in the Wafl or Gadd45 gene, 
while the binding to RGC, MCK and SV40 consensus sequences was hardly 
influenced (Wang and Prives, 1995). Therefore, phosphorylation of Ser315 
could induce selective, sequence-specific, DNA binding of p53.
Protein kinase С (PKC) phosphorylates p53 from multiple sites in vitro, but 
all sites are located in the vicinity of pAb421 epitope (aa 371-381). Serines 376 
and 378 of human p53 and corresponding serines (370 and 372) of murine p53 
have been clearly identified as sites phosphorylated by PKC (Baudier et al.,
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1992; Takenaka et al., 1995; Miine et al., 1996; Delphin et al., 1997). Phospho­
rylation by PKC masks рАЬ421 epitope on p53 and also induces sequence- 
specific DNA binding activity of p53 in vitro (Takenaka et a l 1995). In vivo 
situation, however, can be different: in several cell types most of the p53 is 
phosphorylated at PKC site Ser376 (this protein is not recognized by pAb421 
antibody). After induction of p53 activity by ionizing radiation, Ser376 is 
dephosphorylated, but Ser378 remains phosphorylated. This phosphorylation 
pattern forms consensus site for binding to 14-3-3 proteins, which in turn 
activate sequence-specific DNA binding of p53 in vitro (Waterman et al.,
1998). This allows to propose that 14-3-3 proteins can be pAb421-like natural 
activators of p53, association of which with p53 is regulated by phosphoryla­
tion/dephosphorylation at PKC sites.
The serine residue at position 392 of human p53 (equivalent to mouse 
Ser386) was found to be phosphorylated by casein kinase II (CKII; Meek et al.,
1990) and this phosphorylation leads to the activation of sequence-specific 
DNA binding of p53 (Hupp et al., 1992). The biological meaning of phospho­
rylation of Ser392 is not fully understood. Some studies indicate that phos­
phorylation of this site is not needed for wt p53 activities (Fiscella et al., 1994; 
Rolley and Milner, 1994), whereas others show that mutation of СКП site 
reduces p53-dependent transcriptional repression (Hall et al., 1996) and activa­
tion (Hao et al., 1996). Nevertheless, biochemical studies indicated that phos­
phorylation of Ser392 strongly stabilizes p53 tetramer formation in vitro 
(Sakaguchi et al., 1997). It is possible that in normal circumstances (where p53 
is expressed at very low concentration), the tetramerization of protein is subject 
of regulation indeed. Tetrameric p53 in turn, is more efficient for sequence- 
specific DNA binding than its monomeric form. This makes it very difficult to 
evaluate biological effect of mutations of phosphorylation site in assays, where 
p53 protein is overexpressed (which can compensate lower stability of tetram­
er s).
In addition, p53 can be phosphorylated from N-terminus by Raf kinase in 
vitro (Jamal and Ziff, 1995), from N- or C-terminus by TFIIH-associated kinase 
complex САК (Ко et al., 1997; Lu et al., 1997) and also by protein kinase A 
(Adler et al., 1997). In these cases, exact target residues for phosphorylation are 
not known.
2.3.2. Cellular modulators of p53 activity
Activity of p53 is regulated also by many different protein-protein interactions. 
Whereas viral proteins usually cause inactivation of p53, cellular proteins are 
both positive and negative regulators of p53. The possible roles of mdm2, p300 
and 14-3-3 in regulation of p53 were discussed earlier, but in addition to these,
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there are several other proteins that have influence on p53 activities in the cell. 
Some, but not all, of them can physically interact with p53, while others show 
just co-operative effect in activation of p53-dependent transcription or DNA 
binding.
The Wilms’ tumor-suppressor gene product WT1 has been shown to associ­
ate with p53 when both are overexpressed in the same cell (Maheswaran et al.,
1993). Co-expression of p53 and WT1 results in higher steady-state levels of 
p53, an increased level of p53 binding to sequence-specific DNA targets, and 
an enhanced transcriptional activity of p53, but reduces p53-mediated apoptosis 
(Maheswaran et al., 1995). As WT1 is transcription factor itself, the enhance­
ment of p53-dependent transcription can be achieved at higher concentration of 
transactivation domains, when WT1 is localized in the vicinity of promoter 
through interaction with DNA-bound p53. The same scheme of co-operation 
exists also in opposite way. In the case of GADD45 promoter, p53 can contrib­
ute to activation of transcription in two ways: binding directly to its cognate 
DNA sequence in the third intron of the gene (Kastan et al., 1992) and by 
interacting with WT1 protein, binding site of which is in front of the promoter 
(Zhan et al., 1998).
p53 interacts with two components of E2F transcription factors: DPI and 
E2F1 and this interaction inhibits both the p53-dependent and E2F-dependent 
transcription (O’Connor et al., 1995; Sorensen et al., 1996). p53 and E2F1 
proteins cooperate to mediate apoptosis (Wu and Levine, 1994; Kowalik et al.,
1998), which is probably the result of two conflicting signals: p53 induces cell 
cycle block in Gi phase, but E2F1 can induce quiescent cells to enter S phase 
(Johnson et al., 1993). Expression of E2F1 also induces accumulation of p53 
(Kowalik et al., 1998).
There are two other transcription factors which have been reported to 
interact with p53 and enhance its transactivation ability: BRCA1, which binds 
to C-terminus of p53 and enhances both p53-dependent transactivation and 
apoptosis (Ouchi et al., 1998; Zhang et al., 1998), and hypoxia-inducible factor 
l a  (HIF-la), which also induces stabilization of p53 (An et al., 1998). In 
addition, a putative tumor suppressor protein p33ING1 interacts with p53, en­
hances p53-dependent transcription and is needed for efficient growth suppres­
sion by p53 (Garkavtsev et al., 1998). Also c-Abl tyrosine kinase binds to p53 
and increases its transactivation activity. In this case, the kinase activity of 
c-Abl is not needed, because a mutant of c-Abl deficient in kinase activity also 
stimulates p53. Activation of p53 depends on physical interaction between 
c-Abl and p53, which is mediated by proline-rich SH3 domain of c-Abl and 
probably involves proline-rich region of p53 (Goga et al., 1995). The region of 
p53 near to proline-rich domain was recently reported to be involved in regula­
tion of its DNA binding activity (Hansen et al., 1998; Müller-Tiemann et al.,
1998). It is therefore possible that the stimulating effect of c-Abl can be 
achieved by activation of sequence-specific DNA binding of p53.
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Ref-1 and HMG-1 proteins were found to activate sequence-specific DNA 
binding of p53, when fractions of nuclear extract of HeLa cells were tested for 
activation of p53-dependent transcription and DNA binding (Jayaraman et al., 
1997; Jayaraman et al., 1998). Both proteins are quite nonspecific “helpers”, 
which activate DNA binding of various other proteins. Ref-1 is a dual function 
protein which can both regulate the redox state of a number proteins and 
function as a DNA repair apurinic/apyrimidinic endonuclease (Demple et al., 
1991; Xanthoudakis and Curran, 1992; Xanthoudakis et al., 1992). As DNA 
binding activity of p53 depends on its redox state (reduced p53 binds effi­
ciently, while oxidized p53 binds very poorly; Hainaut and Milner, 1993), the 
stimulatory effect of Ref-1 is, at least partially, achieved by redox regulation of 
p53. On the other hand, Ref-1 can stimulate DNA binding of wt p53 also by a 
redox-independent mechanism (Jayaraman et al., 1997), which probably 
involves modulation of activity of С-terminal domain of p53. HMG-1 belongs 
to a family of highly conserved chromatin-associated nucleoproteins which 
bend DNA and facilitate the binding of various transcription factors to their 
cognate DNA sequence (Onate et al., 1994; Zwilling et al., 1995; Zappavigna 
et al., 1996). p53 also bends DNA when bound to its cognate sequence 
(Balagurumoorthy et al., 1995; Nagaich et al., 1997), therefore it is very likely 
that effect of HMG-1 in stimulation of p53 involves bending of DNA.
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3. RESULTS AND DISCUSSION
3.1. Concentration-dependent activation 
of transcription by p53 (I)
As described in review of literature, p53 can both activate and repress tran­
scription. The p53 binding site in the vicinity of promoter is needed for activa­
tion of transcription, while the promoters repressed by p53 usually do not 
contain p53 binding sites. However, in the case of Drosophila Krüppel protein, 
it has been shown that the same protein can activate or repress the same 
promoter. The promoter is activated by low concentration of the Krüppel and is 
repressed when Krüppel is expressed at high concentration (Sauer and Jackie,
1991). To test whether activation of p53 responsive promoter is similarly de­
pendent on concentration of p53 protein, we cotransfected cells with various 
amounts of wt p53 expression plasmid and with reporter plasmid containing 
high-affinity p53 binding site CON in front of the minimal promoter and CAT 
gene. In Cos7 cells, which contain endogenous wt p53, transfection of low 
amount of p53 expression plasmid (1-100 ng) lead to slight activation of CAT 
gene expression, but transfections with higher amounts of wt p53 expression 
plasmid (1 and 5 pg) caused repression of the promoter far below the basal 
activity (I, Fig. 2). We also confirmed that the amount of p53 protein in the cell 
correlates with amount of expression plasmid used in transfections (I, Fig. 1). 
Next we tested whether the repression p53-responsive promoter depends on the 
presence of transactivation domain of p53. Although exact mechanism of re­
pression of other promoters by p53 is not known, it has been shown that p53 
deficient for transactivation is also unable to repress transcription (Subler et al.,
1994). Therefore, we deleted the transactivation domain from p53 and asked 
whether this truncated protein is able to repress basal transcription from 
p53-responsive promoter. Again, high amount of expression plasmid (1 and 
5 ^g), encoding N-terminally truncated p53, caused repression of basal CAT 
gene transcription from reporter plasmid (I, Fig. 2). This result shows that 
repression of p53-responsive promoter is independent from transactivation 
domain and is therefore probably different from the mechanism of repression 
described previously. We also studied the dose-dependent effects of transac­
tivation by wt p53 in Saos2 cells, which do not contain endogenous p53. Also 
in this system the moderate amount of wt p53 (10-100 ng of expression 
plasmid) gave maximum activation of transcription, whereas higher amounts of 
expression plasmid caused loss of transactivation (I, Fig. 3; II, Fig. 2). We were 
not able to test the influence of N-terminally truncated p53 in this system, 
because of very low basal activity of reporter promoter in Saos2 cells.
One possible way to explain the dose-dependent effect of p53 on transcrip­
tion is to assume that the transfected DNA itself, and not the protein expressed
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from it, is responsible for this effect. The plasmid DNA used for transfections 
contains eukaryotic promoter and is therefore able to bind cellular proteins 
essential for transcription. This could in turn be the real reason for the tran­
scriptional inhibition described by us. To test the possible side effects of ex­
pression plasmid we transfected Saos2 cells with different amounts of wt p53 
expression plasmid, keeping total amount of plasmid the same in all transfec­
tions. For that we used the same type of expression vector, which contains most 
of the p53 cDNA sequences, but it also contains 750 bp insertion between ATG 
codon and p53 coding region, leaving the latter out of frame. Therefore, no p53 
protein was expressed, but cDNA sequences were still present. Also in the 
context of high amount of expression plasmid in the cell, the best activation of 
transcription by wt p53 was achieved at moderate amounts of the pro­
tein (I, Fig. 3). Therefore we concluded that concentration-dependent activation 
of transcription by p53 is indeed caused by different amounts of p53 protein 
and not by different amounts of expression plasmid used in transfections.
Taken together, these results show that concentration of p53 can be a factor 
modulating the level of expression from p53-resposible promoter. Later studies 
by others in in vivo model systems also demonstrated discordance between the 
transcriptional activity of p53 and its protein level in the cells treated with UV 
irradiation. Expression of p53 target genes was observed only in the cases, 
where moderate level of p53 was induced. After induction of high level of p53 
protein, activation of p53 target genes (Mdm2 and Wafl) was either signifi­
cantly delayed or transcription of these genes was not activated at all (Lu et al., 
1996; Reinke and Lozano, 1997; Wu and Levine, 1997; Saucedo et al., 1998).
3.2. Oligomerization of p53 is necessary 
for inhibition of transactivation (II)
We continued the work on concentration-dependent transactivation attempting 
to determine the structural domains of p53 which are needed for this activity. 
Our initial data showed that all mutants which oligomerization domain deleted 
were able to activate transcription and this activity was not inhibited at high 
protein concentrations. To test more precisely the role of oligomerization in 
loss of transactivation at high protein concentration, we made deletion mutant 
Д324-355, which encodes p53 without the oligomerization domain. We also 
used another p53 mutant, 1262, which contains four point mutations in the oli­
gomerization domain and has been shown to be monomeric in solution (Stür­
zbecher et al., 1992). First we confirmed that these mutants are monomeric 
indeed. For that we transfected cells with appropriate expression constructs, 
lysed the cells with mild detergent, crosslinked proteins with glutaraldehyde 
and separated them in the SDS-polyacrylamide gel. After transferring proteins
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to nitrocellulose filter, we detected protein complexes by Western blotting with 
anti-p53 antibodies pAb240 and pAbl801 and identified mono-, di- and tetram- 
ers according to molecular weight markers (П, Fig. IB). Next we cotransfected 
Saos2 cells with different amounts of expression plasmids together with p53- 
responsive CAT reporter construct and determined CAT activity 24 hours later. 
In contrast to wt p53 the monomeric mutants did not show any loss of transac- 
tivating activity at high protein concentration (II, Fig. 2). Because different 
mutants could have different expression levels or half-lives in the cell, we 
needed to determine whether “high” and “low” concentration of different mu­
tants has the same meaning in every case. We determined relative amounts of 
p53 protein in every transfection by Western blotting and quantitated protein 
signals with Fluorlmager. One half of cells from every transfection was used 
for CAT assay and the second half was lysed for Western blotting. We detected 
both p53 and TBP proteins with mixture of monoclonal antibodies on the same 
blot. 43kD TBP band was easily separable from p53 bands and was used for 
determination of amount of total protein in particular sample. Next we normal­
ized the signals of p53 bands according to the amount of total protein (TBP 
band from Western blot) and efficiency of transfection (determined for every 
series of transfection by ß-galactosidase assay). These data showed that the 
same amount of different expression constructs produced roughly the same 
amount of different p53 proteins (П, Fig. 3) indicating that all CAT assays were 
performed in comparable conditions.
It has been shown that oligomerization of p53 is needed for interaction with 
mdm2 protein (Marston et al., 1995). Therefore it was possible that the loss of 
transactivating activity of wt p53 could be a result of mdm2-dependent inacti­
vation of p53 and monomeric mutants retained their activity because they were 
resistant to the mdm2 expression. To evaluate possible role of mdm2 protein in 
regulation of concentration-dependent transactivation by p53, we used mutant 
AI, which is unable to interact with mdm2 and is resistant to mdm2-dependent 
inactivation and degradation (Marston et al., 1994; Kubbutat et al., 1997). AI 
mutant behaved similarly to wt protein, indicating that mdm2 is probably not 
involved in inhibition of transactivation by p53 at high protein concentrations 
(П, Fig. 2C). We also tested whether changes in specific DNA binding of p53 
are responsible for loss of transactivation at high expression level and found 
that DNA binding activity of p53 correlates with amount of protein in the cells, 
but not with the transactivating activity of p53 (II, Fig. 4).
Because p53 has to bind proteins of the basal transcription machinery to 
activate transcription, we propose that at overexpression conditions p53 can 
titrate out some basal transcription factor(s), amount of which is limited in the 
cell. This phenomenon is characteristic for many transcriptional activators and 
is known as squelching (Ptashne, 1988). At optimal concentrations every acti­
vator molecule bound to the test promoter is also bound to the target mole­
cule^) (for example TFITO complex). In excess of the activator most of activa­
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tor proteins bound to the test promoter are not bound to the target molecule(s) 
because of limited amount of the latter. Therefore, activation of the test pro­
moter is inhibited as compared to the optimal concentration of activator. On the 
other hand, high levels of monomeric p53 mutants did not cause the effect of 
squelching. Possible explanation here is that monomeric p53 can not interact 
with transcription machinery at all and therefore is unable to squelch basal 
transcription factors. If it is so, how can monomeric p53 activate transcription? 
p53 binding DNA consensus sequence contains two tandem decameric ele­
ments, each containing two pentameric inverted repeats. Therefore, the DNA 
itself can be a factor, which brings four p53 monomers together and p53 could 
gain the ability to interact with transcription machinery only after binding to the 
DNA consensus sequence. Increasing concentration of monomeric p53 in the 
cell could increase probability that more test promoters are bound to multiple 
p53 monomers, which in turn assures higher transcription efficiency from the 
promoter.
The second possibility, which should be kept in mind, is that unlike wt 
protein monomeric p53 is not able to induce apoptosis. Therefore the loss of 
transactivating activity of wt p53 could be an accompanying effect of the 
beginning of apoptosis. One could argue that monomeric p53 retains its 
transactivating properties, but does not induce apoptosis and in the latter case 
the transactivating activity of wt p53 is not involved in induction of apoptosis. 
However, we were not able to detect differences in viability of cells 24 hours 
after transfection, when CAT assays were done.
3.3. Mutant p53 can inhibit activities of p53 
without heterooligomerization (III)
In human tumors p53 protein has been often mutated. Because it is expressed 
from both alleles, the overall content of intracellular p53 can be either wild- 
type (wt), mixture of wt and mutant p53 or mutant p53 only (when both alleles 
are mutated or one allele is deleted). In the case of coexpression of mutant and 
wt p53 it has been shown that mutant p53 can drive wt p53 to mutant conforma­
tion (Milner and Medcalf, 1991) and the transactivation function of wt p53 is 
inhibited by mutant p53 (Kern et al., 1992). It is generally believed that the 
mechanism behind this effect is that mutant p53 proteins form heterooligomers 
with wt proteins, which are less active in transcriptional activation than ho­
mooligomers of the wt protein. If this is the case, the monomeric p53 would be 
insensitive to mutant protein, because heterooligomers cannot form. To test this 
we carried out series of transfections in Saos2 cells, where monomeric mutant 
Л324-355 was used as activator of transcription and it was со-expressed with 
three different cancer-associated point mutants of p53. All transfections con­
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tained also two reporter plasmids. One of them had high-affinity p53 binding 
site CON in front of minimal promoter and CAT gene, which was used for 
measuring of p53-dependent transcription. Another reporter contained CMV 
promoter in front of ß-galactosidase gene, which indicated the activity of 
p53-independent transcription. To our surprise, all point mutants tested clearly 
inhibited p53-dependent transcription when compared to co-expression with 
empty expression plasmid (Ш, Fig. 2A). p53-independent transcription was not 
changed by mutants (1П, Fig. 4). To get more insight into the nature of this 
inhibition we deleted N-terminal transactivation and/or С-terminal regulatory 
domain(s) of the Trp248 mutant p53 protein (III, Fig. 1) and tested them in our 
assay. When either N- or C-terminus was deleted, the mutant could still inhibit 
the transcriptional activity of the ЛЗ24-355. However, when both termini were 
absent, the mutant was not able to repress the Д324-355 activity any more (III, 
Fig. 2B). Reporter plasmid used in these experiments contained synthetic p53 
binding site CON in front of the adenovirus E2 promoter. This binding site 
binds p53 very efficiently, but does not occur in natural promoters. To test our 
finding in more physiological context, we also performed the same kind of 
experiments using a reporter plasmid containing 2.4 kb fragment from human 
Wafl promoter in front of the CAT gene and the result obtained was essentially 
the same: only the mutant with both termini deleted was unable to inhibit trans­
activation by monomeric p53 (III, Fig. 3).
In order to clarify the relevance of our results in more biological assay, we 
tested the influence of point mutants to the growth suppression activity of 
Д324-355. It has been reported that monomeric p53 expresses clear growth 
suppressing activity, although slightly less than the wt protein (Shaulian et al., 
1993; Thomas et al., 1996). In our hand the wt p53 inhibited colony formation 
almost entirely and Д324-355 reduced the number of colonies approximately 
50% as compared to the transfections with the resistance marker only. When 
either Trp248, its N-terminal or С-terminal deletion mutants were added to the 
transfection mixture, they inhibited the growth suppressing activity of the 
monomer (Ш, Fig. 8). The Trp248 mutant with both termini deleted was in 
itself able to reduce the colony number therefore, its effect to the activity of the 
monomer could not be examined.
Next we tested, whether mutant proteins change the expression level or 
localization of monomeric mutant Д324-355. Because most of the deletion 
mutants used had different electrophoretic mobilities in SDS-gel, we were able 
to control the expression level of our proteins by Western blotting. We did not 
detect any change of expression of Д324-355 when different mutants were co­
expressed (Ш, Fig. 5). We also tested whether Д324-355 was located in the 
nucleus during coexpression of different mutants. For this purpose we coex­
pressed deletion mutants of Trp248 together with Д324-355 protein and deter­
mined localization of the latter by immunofluorescent staining with antibodies, 
epitopes of which were lacking in Trp248 mutants. In all cases Д324-355 was
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located in the nucleus (Ш, Fig. 6). We also confirmed that A324-355 did not 
form oligomers with Trp248 deletion proteins. Cells cotransfected with A324- 
355 and deletion mutants of Trp248 were lysed, crosslinked with glutaral- 
dehyde, divided between two equally loaded gels, electrophoresed and blotted 
to nitrocellulose. By using Western blotting with different primary antibodies 
we were able to show that in the case of coexpression with point mutants the 
A324-355 remains monomeric in solution (III, Fig. 7).
Taken together, we have shown that in coexpression conditions mutant p53 
can inhibit the activity of functional p53 without heterooligomerization and this 
effect is not caused by improper expression or localization of the latter. This 
inhibition was not extended to transcription from p53-independent promoter. 
We propose that the mutant form of p53, when expressed at high level, may 
deplete cells from cofactors necessary for p53 to activate transcription, but not 
needed for transcription in general. The transactivating function of p53 can be 
modified by different factors. The c-Abl and WT-1 are cellular proteins binding 
wt p53 and activating its transactivation function (Maheswaran et al., 1993; 
Goga et al., 1995; Maheswaran et al., 1995). Recently, new activators of p53 
were identified, including Ref-1 (Jayaraman et al., 1997), HMG-1 (Jayaraman 
et al., 1998), p33ING1 (Garkavtsev et al., 1998), BRCA1 (Ouchi et al., 1998; 
Zhang et al., 1998) and 14-3-3 (Waterman et al., 1998). It is not known, 
whether they can interact with point mutants of p53 or with monomeric p53. 
Therefore we have no clues to speculate, could one of these activators be 
depleted from cells by mutant p53 in our experiments.
Two explanations can be proposed to the fact that Trp248 mutant, truncated 
at both termini, cannot inhibit Д324-355 mediated transactivation. First, the 
deletions from both ends of the protein may affect the overall conformation of 
the molecule making it unable to bind the specific cofactor. The other explana­
tion comes from a hypothesis according to which N- and C-termini are close to 
each other in 3-dimensional structure. They could generate a binding site for 
this proposed cofactor and only the deletions of both of them abolish the 
binding of the cofactor. Alternatively, wt p53 may need a specific modification 
for its activity rather than binding to a specific cofactor. If p53 needs to be 
phosphorylated in order to activate transcription, the inhibitory effect of point 
mutants to A324-355 mediated transcription may relay on the saturation of the 
modifying enzymes. Following this line two or more modifications are needed 
for transactivation by p53 — at least one for N- and the other for C-terminus. If 
even one of these possible modifying enzymes is depleted by mutant p53, the 
functional p53 cannot activate transcription. Only in the case of Trp248, trun­
cated from both termini, the A324-355 retains its activity, because the former is 
not able to bind modifying enzyme(s) needed for modification of p53.
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4. CONCLUSIONS
The present study can be summarized as follows:
1. We have shown that the best activation of p53-responsible promoter is 
achieved by optimal concentration of p53 protein. p53 loses its transactivating 
activity at high protein concentrations.
2. Inhibition of transactivation at high protein concentration is not the result of 
loss of sequence-specific DNA binding activity of p53 and is not caused by 
mdm2-dependent inactivation of p53.
3. Oligomerization of p53 is involved in inhibition of transactivation at high 
protein concentrations.
4. Cancer-associated point mutants of p53 can inhibit activities of functional 
p53 without heterooligomerization.
5. Both N- and C-termini of mutant p53 are involved in the inhibition of activi­
ties of monomeric p53. Only the mutant with both termini deleted is inactive 
for this inhibition.
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KASVAJATE SUPRESSORVALGU p53 OMADUSED 
TRANSKRIPTSIOONI AKTIVAATORINA
Kokkuvõte
p53 on rakuline valk, mille peamiseks funktsiooniks on rakkude normaalse 
kasvu ja  jagunemise kontrollimine. Koos funktsionaalse p53 kadumisega 
rakus suureneb kasvaja arenemise tõenäosus, mida kinnitab ka fakt, et üle 
50%-s kasvajatest on p53 geen muteerunud. Mutatsioonid on kõige sage­
dasemad p53 DNA-d siduvas domäänis ning jagunevad valdavalt kahte tüüpi: 
mutatsioonid, mis muudavad otseselt DNA-ga kontakteeruvat aminohappe- 
jääki, ning mutatsioonid, mis lõhuvad domääni üldise struktuuri. Et aktiivne 
p53 moodustub nelja monomeeri tetramerisatsioonil, siis heterosügootses 
rakus moodustub mutantse ja  normaalse p53 kompleks. Selline kompleks on 
kas ainult osaliselt funktsionaalne või täiesti inaktiivne. Sellega seletub ka 
mutantse p53 võime inaktiveerida normaalse valgu funktsioone. p53-l on 
mitmeid aktiivsüsi, millest seni on kõige paremini uuritud tema võimet mõju­
tada erinevate geenide transkriptsiooni. p53 aktiveerib mitmeid geene, kuid 
on ka paljude repressoriks. Transkriptsiooni aktiveerimiseks peab p53 seon­
duma basaalsete transkriptsioonifaktoritega ning järjestusspetsiifiliselt DNA- 
ga. Käesolev doktoritöö põhineb kolmel uurimusel, millest kahes me selgi­
tasime p53 poolt aktiveeritava transkriptsiooni sõltuvust p53 kontsentrat­
sioonist rakkudes ning kolmandas näitasime, et normaalse p53 funktsiooni 
häirib mutantne valk isegi siis, kui need kompleksi ei moodusta. Lühidalt olid 
tulemused järgmised.
p53 aktiveerib transkriptsiooni optimaalse kontsentratsiooni juures. Kui 
p53 valku on rakus üle optimaalse hulga, siis p53-st sõltuv transkriptsiooni 
aktivatsioon väheneb oluliselt. Me näitasime, et selline aktiivsuse langus pole 
tingitud p53 DNA-d siduva võime vähenemisest ning tõenäoliselt samuti 
mitte p53 negatiivse regulaatorvalgu mdm2 ekspressioonist. p53 deletsioon- 
analüüsil leidsime, et sellise inhibitsiooni tekkeks on vajalik p53 oligomeri- 
seerumine: monomeersed mutandid aktiveerisid transkriptsiooni ka siis, kui 
neid ekspresseerida kõrgel kontsentratsioonil.
Ekspresseerides samaaegselt koos nii mutantset kui ka normaalset p53 
valku, moodustavad need funktsionaalselt inaktiivse heterooligomeeri. Et väl­
tida heterooligomeeride teket, kasutasime oma katsetes transkriptsiooni akti­
veerimisel monomeerset p53. Sellise valgu funktsiooni ei peaks häirima 
mutantne p53, sest heterooligomeere tekkida ei saa. Selgus aga, et mutantne 
p53 on võimeline inaktiveerima ka monomeerse valgu funktsioone. Mutandi 
inhibeeriv mõju kadus, kui sellest olid deleteeritud nii transaktiveeriv kui ka 
regulatoome domään. Kumbki deletsioon üksinda ei kaotanud mutantse p53 
võimet inhibeerida monomeerse p53 transaktiveerivat aktiivsust. Samas ei
52
mõjutanud mutantse p53 (ega tema deletsioonimutantide) ekspressioon p53-st 
mittesõltuva transkriptsiooni toimumist. Saadud andmed lubavad oletada, et 
p53 vajab oma aktiivsuse saavutamiseks mingeid rakulisi kofaktoreid, mille 
hulk on limiteeritud ning mutantne p53 võib need lihtsalt välja tiitrida.
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Tumor suppressor protein p53 binds to DNA in a sequence-specific manner and activates transcription 
from promoters near its binding site. It is also known to repress promoters lacking the p53-binding site. 
In this study, we demonstrate that p53 can act as a transcriptional activator or repressor in vivo using the 
same reporter with the DNA-binding site CON and these effects depend on the amount of p53 expressed. 
Both in Saos2 and Cos7 cells, lower concentrations o f p53 lead to activation and higher concentrations 
lead to repression of the model promoter containing the consensus p53-binding site CON. The N-terminal 
part of p53 is necessary for the transcriptional activation. It is not needed, however, for the repression of 
the same promoter, indicating that different domains of p53 are involved in activation and repression.
Keywords: oncoprotein; p53; transcription; concentration dependence; chloramphenicol-acetyltransferase
assay.
The human tumor suppressor protein p53 is able to modulate 
RNA transcription both vivo and vitro (Agoff et al., 1993; Barak 
et al., 1993; Chin et al., 1992; Deb et al., 1992, 1994; El-Deiry 
et al., 1993; Jackson et al., 1993; Juven et al., 1993; Kastan et 
al.. 1992; Mack et al., 1993; Okamoto and Beach, 1994; Ragi- 
mov et al., 1993; Subler et al., 1992, 1994; Zambetti et al.,
1992). Wild-type p53 binds to double-stranded DNA homolo­
gous or identical to the consensus sequence 5'-RRRC(A/T)(A/ 
T)GYYYN,,„, ,RRRC(A/T)(A/T)GYYY-3' in a sequence-spe- 
cific manner (El-Deiry et al., 1992; Funk et al., 1992). It has 
been shown that wild-type p53 can transactivate the promoters 
containing its DNA-binding site due to interaction o f the p53 N- 
terminal region with the TATA-box-binding protein (TBP; Mar­
tin et al.. 1993; Subler et al., 1994; Truant et al., 1993; Unger 
et al.. 1993). According to the current model for its function in 
cell growth inhibition. p53 activates transcription of the WAFI 
iCIFI) gene, the product of which in turn regulates G1 cyclin- 
dependent protein kinases and proliferating cell nuclear antigen 
(El-Deirv el al.. 1993; Xiong et al., 1993; Harper et al.. 1993; 
Li et al..’ 1994).
In contrast. p53 has been shown to repress several viral and 
cellular promoters containing no known p53-binding sites 
(Agoff et al.. 1993: Deb et al.. 1992; Jackson et al.. 1993; Mack 
et al.. 1993; Ragimov et al., 1993; Subler et al., 1992. 1994). 
This effect has been explained as the ‘squelching’ of basal tran­
scription factors TBP and transcription factor IID (TFIID) by 
interaction of N-terminal amino acids o f p53. Although both 
TATA-box-mediated and pyrimidine-rich-initiator-element-me- 
diated transcription need TBP for initiation, only the former is 
susceptible :<> repression by wild-type p53 (Mack et al., 1993).
Corrcs/Nim/enct’ lo T. M aimets. Institute o f  M olecular and Cell Biol­
ogy. Estonian Biocentre. Tartu University. Riia 23. Tartu. EE-2400 Es­
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Abbivviulions. CAT. chloramphenicol acetyl transferase; HSV. herpes 
simplex virus: IMEM. Iscove's modified Eagle’s m edium : TBP. TATA- 
hox-hinding protein.
HiK.yme. Chloram phenicol acetyltransferase (EC 2.3.1.28).
This indicates that other mechanisms than ‘squelching’ o f tran­
scription factors can be additionally involved in transcriptional 
repression by the p53 protein.
Mutations in the p53 gene are the most common genetic 
alterations in human tumors (Hollstein et al., 1991; Nigro et al.,
1989). While wild-type p53 protein is able to suppress cell 
growth and transformation, the tumor-derived mutants have lost 
these properties and can support transformation of cells (Jenkins 
et al., 1985; Hinds et al., 1989). Recently, it was shown that 
most o f the p53 mutations found in tumors occur at amino acids 
directly in contact with DNA or at residues stabilizing the con­
formation of the DNA-binding domain (Cho et al., 1994). In 
both cases. p53 is not able to bind its specific DNA target, which 
leads to its inability to activate the genes responsible for cell 
cycle control (i.e. WAFI/CIPI). However, the p53 gene is not 
mutated in all cases in any particular type o f human tumor. Even 
in these types of tumors, which most often contain mutations in 
the p53 gene, the p53 gene is wild-type in at least one third of 
cases (Hollstein et al.. 1994). Clearly, mutations in p53 are not 
the only reason for loss of cell proliferation control in these 
cells.
In this study, we investigated the effects of p53 concentration 
on its transcription-modulating activities in vivo. We were inter­
ested in how the concentration of p53 protein expressed in cells 
modulates its ability to activate/repress RNA transcription from 
a reporter plasmid containing the chloramphenicol acetyl­
transferase gene under the control of the adenoviral E2 promoter 
and the consensus p53-binding site CON (Hink et al.. 1992). We 
demonstrate that transcription from the reporter plasmid can be 
activated or repressed by p53 in vivo and these effects depend 
on the amount o f p53 expressed in cells. Lower concentrations 
of p53 lead to the activation of promoter in the cells lacking 
endogenous p53 (Saos2) and additional activation in the cells 
having high levels o f endogenous p53 (Cos7). Higher concentra­
tions of p53 lead to the repression of the same promoter in Cos7 
cells and loss o f activation in Saos2 cells. Truncated p53 protein 
without the 39 N-terminal amino acids essential for transactiva­
tion and TBP binding has lost its transactivating properties, but
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is still able to repress transcription. We also demonstrate that the 
p53 concentration per se, in addition to mutations in its amino 
acid sequence, can be a factor modulating p53-dependent tran­
scription, which could lead to the loss of cell cycle control in 
tumors.
MATERIALS AND METHODS
Plasmid constructs. Expression plasmid pCG-Hwt contains 
human wild-type p53 cDNA downstream of the cytomegalovirus 
immediate early promoter and mRNA leader sequence of the 
herpes simplex vims (HSV) thymidine kinase gene. pCG-dl39 
was created by PCR and encodes the mutant p53 protein with 
deletion of the first 39 amino acids. Expression, appropriate mo­
lecular mass, and nuclear localization of proteins were checked 
by Western blotting and immunofluorescence staining. Plasmid 
pCG-RN was crcated by inserting a 750-bp bovine papillomavi­
rus E2 sequence into pCG-Hwt. This insert replaces DNA se­
quences coding for amino acids 1—58 of p53 and causes 
frameshift of p53 sequences.
The E2-100 CAT reporter plasmid was provided by Dr J. 
Jenkins and was described earlier (Tarunina and Jenkins, 1993). 
It contains the p53 consensus DNA-binding site CON (Funk et 
al., 1992) and modified adenovirus E2 promoter in front of the 
chloramphcnicol acetyltransferase (CAT) gene.
Cell culture and transfection. Cos7 and Saos2 cells were 
cultured in Iscove’s modified Eagle’s medium (1MEM) supple­
mented with 10% fetal calf serum and 100U/ml penicillin and 
streptomycin. Cells were maintained at 37 °C in humidified 5% 
COj atmosphere. Cells were transfected by electroporation as 
follows: 5— lOXlO6 cells were collected from 70% confluent 
cell dishes and suspended in IMEM containing 5 mM Na-Bes 
[/V,Ar-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid], 50 ng 
sonicated salmon sperm DNA, and expression and reporter plas­
mids were added to 250 pi cell suspension and the cells were 
pulsed (1 mF and 190 V for Cos7 cells, 1 mF and 210 V for 
Saos2 cells) using an Invitogene electroporator. 100 ng or 2 |ig 
E2-100 CAT reporter plasmid was used for transfection of Cos7 
or Saos2 cells, respectively. After electroporation, cells were re­
suspended in IMEM and transferred to growth conditions on 10- 
cm-diameter cell culture dishes.
Cell viability was determined 24 h after transfection by try­
pan blue exclusion. No correlation between cell viability and the 
amount of transfected plasmids was found (7—10% dead cells 
in all cases).
Western blotting. Cells were lysed 24 h after transfection in 
200 ц1 SDS loading buffer (50 mM Tris/HCl, pH 6.8, 100 mM 
dithiothreitol, 2% SDS, 0.1 % bromophenol blue, 10% glycerol) 
and boiled for 3 min. 10% of the lysate was separated by SDS/ 
PAGE in a 12% polyacrylamide gel. Proteins were transferred to 
a nitrocellulose filter and detected with a mixture of monoclonal 
antibodies pAb421 (Harlow et al., 1981), pAb1801 (Banks et ■ 
al., 1986), and pAb240 (Gannon et al„ 1990). Rabbit anti-mouse 
IgG secondary antibody and ,5S-labeled protein A were used for 
quantification of p53 protein. Quantitation of data was per­
formed with a Phosphorlmager using the ImageQuant software 
(Molecular Dynamics).
CAT assay. Cells were collected 24 h after transfection. The 
lysis o f cells and CAT assays were performed by standard meth­
ods (Sambrook ct al., 1989). One third of the Cos7 cell lysate 
and one half o f the Saos2 cell lysate were used in the CAT assay. 
Enzyme reactions with D-threo(dichloro-[l-,4CJacetyl)chloram- 
phenicol and acetyl-coenzyme A were incubated at 37 °C for 1 h 
(Cos7 lysates) or 3 h (Saos2 lysates). Quantitation of data was 
performed using a Phosphorlmager.
A
ng of pCG-Hwt
1 2 3 4 5 6
В
ng of pCG-dl39
1 2 3 4  5 6
С
Amount of transfected plasmids (ng)
Fig. 1. W estern blot o f cell lysates transfected with different am ounts 
o f expression plasmids. 0 (lane 1), 1 (lane 2), 10 (lane 3), 100 (lane 4), 
1000 (lane 5) or 5000 (lane 6) ng plasmid pCG-Hwt (A) or pCG-dl39 
(B) were transfected into Cos7 cells. The filter was probed with anti- 
p53 monoclonal antibodies, rabbit anti-mouse antibodies, and ” S-labeled 
protein A. (C) Quantitation of data from A (□) and В (Д) with Phos­
phorlmager.
RESULTS AND DISCUSSION
Several authors have shown that wild-type p53 can activate 
transcription from promoters containing the consensus DNA- 
binding sequence (Barak et al., 1993; Deb et al., 1994; El-Deiry 
et al., 1993; Kastan et al., 1992; Juven et al., 1993; Zambetti et 
al., 1992) and can repress promoters without such a site (Agoff 
et al., 1993; Jackson et al., 1993; Mack et al., 1993; Ragimov 
et al., 1993; Subler et al., 1992). The interpretation for p53- 
dependent repression o f transcription is that p53 binds to TBP 
and drives it to promoters near the p53-binding site, therefore 
‘squelching’ basic transcription factors from promoters not con­
taining the p53-binding site. Usually, the amount o f p53 expres­
sion plasmid used in these experiments was high (5 - 1 0  pg/ 
transfection).
Cos7 cells were transfected with different amounts o f the 
p53 expression construct pCG-Hwt, containing human p53 
cDNA under the control of the cytomegalovirus immediate early 
promoter and the HSV thymidine kinase mRNA leader se­
quence. Western blotting of the cell lysates was used to demon­
strate that in the range 1 ng to 5 pg expression plasmid used 
for transfection, the amount o f protein expressed increased 
(Fig. 1 A, lanes 2—6, and Fig. 1C).
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We also constructed a deletion mutant of human p53, pCG- 
dl39, which encodes the protein lacking the N-terminal 39 amino 
acids. These sequences have been shown to be essential for tran­
scriptional fran.t-activating properties of p53 and contain the 
binding site for TBP (Liu et al., 1993; Unger et al., 1993). 
Amino acid residues Leu22 and Trp23 have been shown to be 
the most critical residues for the transactivation activity (Lin et 
al., 1994). Transfection of Cos7 cells with increasing amounts 
of this construct also leads to an increase in the level of protein 
expressed (Fig. IB, lanes 2 - 6 ,  and Fig. 1C). The band ob­
served in lane 1 of Fig. 1A and the upper band in Fig. 1 В corre­
spond to endogenous p53 from Cos7 cells.
Immunofluorescent staining of the transfected cells showed 
that the efficiency of transformation (about 30% cells 
transfected) did not depend on the amount of expression plasmid 
used (data not shown). Therefore, the increase in the level of 
protein shown in Fig. 1 is a real increase of the intracellular 
protein concentration. Similar results were obtained with human 
Saos2 cells lacking endogenous p53 sequences (Masuda et al., 
1987; data not shown). The level of expression of p53 in these 
cells was lower because of lack of amplification of the expres­
sion plasmid in Saos2 cells.
We tested whether p53 expressed from transfected plasmid 
could change the transactivation o f the promoter by endogenous 
p53 protein in Cos7 cells (Fig. 2). These cells express endoge­
nous p53 protein at a level that is sufficient to activate the exog­
enous E2 promoter containing the specific p53-binding site 
(Fig. 2A, lane b). The additional expression of a small amount 
of exogenous wild-type p53 causes a slight additional activation 
of transcription (Fig. 2A, lanes 1 and 2). The expression of high 
amounts of p53 protein in Cos7 cells causes repression of tran­
scription far below the basal level (Fig. 2A, lanes 4 and 5, and 
Fig. 2C). This experiment shows that high concentrations of p53 
are able to reverse the transactivating effects caused by endoge­
nous monkey p53 protein in Cos7 cells.
It has been shown recently that both transactivating and 
oligomerization domains of the p53 protein are needed for the 
repression of human cytomegalovirus immediate early promoter 
containing no p53-binding sequences (Subler et al., 1994). We 
tested whether the transactivating domain of p53 is also needed 
for the transcriptional repression of the promoter with the p53- 
binding site described here. For this purpose, we constructed 
the expression vector pCG-dl39, encoding human p53 protein 
without the N-terminal 39 amino acids. These amino acids are 
essential for the transcriptional transactivation activity of p53 
and binding of the basal transcription factor TBP (Liu et al., 
1993; Unger et al., 1993). The truncated protein is able to re­
press the basal level of reporter transcription caused by endoge­
nous p53 protein in Cos7 cells (Fig. 2B , lanes 4 and 5, and 
Fig. 2C). Phosphorlmager quantitation of three independent 
CAT assays (both with pCG-Hwt and pCG-dl39) is shown in 
Fig. 2C. These results show that the transcriptional repression 
of promoters by high concentration of the p53 protein is inde­
pendent from the transcription-activation domain of the p53 pro­
tein.
We also studied the dose-dependent effects of human p53 
protein on CAT gene transcription in Saos2 cells. Fig. ЗА shows 
that the transactivating effect of p53 in Saos2 cells depends on 
the concentration of protein in the cells. The activating effect 
appears at a relatively low level of the expression construct used 
(Fig. ЗА, lanes 3 and 4). Higher amounts of expression plasmid 
used lead to the loss of activation of transcription in the same 
system (Fig. ЗА, lanes 5 -7 ) .
One possible way to explain the dose-dependent effect of 
p53 on transcription described by us is to assume that the 
transfected DNA itself, and not the protein expressed from it, is
ng o f pCG-Hwt
Amount of transfected plasmids (ng)
Fig. 2. Dose-dependent effect o f p53 protein on CAT gene transcrip­
tion in Cos7 cells. Cos7 cells were transfected with expression plasmids 
pCG-Hwt (A) or pCG-dl39 (B) and 100 ng reporter plasmid E2-100 
CAT. 1 (lane 1). 10 (lane 2), 100 (lane 3), 1000 (lane 4) or 5000 (lane 
5) ng expression plasmid were used. Lane b in A shows the basal CAT 
activity o f Cos7 cells transfected with reporter plasm id only. (C) Quanti­
tation o f data from three independent transfection experim ents with 
pCG-Hwt (empty colum ns) and pCG-dl39 (dotted columns).
responsible for this effect. The plasmid DNA used for transfec­
tions contains the eukaryotic promoter and is therefore able to 
bind cellular proteins essential for transcription; this could in 
turn be the real reason of the described transcriptional inhibition. 
However, we have shown that this is not the case. Two sets of 
experiments were performed. We transfected Saos2 cells with 
different amounts of wild-type p53 expression plasmid, keeping 
the total amount of plasmid (5 |ig, in addition to 2 ng reporter 
plasmid E2-100 CON) the same in all transfections. For this 
we used a plasmid pCG-RN containing most o f the p53 cDNA 
sequences, but which did not express them as protein because 
of a 750-bp DNA cloned between ATG and p53 leaving the 
latter out of frame. Therefore, no p53 protein sequences were 
expressed from this plasmid, but the DNA sequences were still 
present. As shown in Fig. 3B and C, the effect of p53 protein 
concentration evident in Fig. 2 A and Fig. ЗА was also detecta-
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F ig .3 . Dose-dependent effect o f p53 on CAT gene transcription in 
Saos2 cells. (A) Saos2 cells were transfected with U (lane 1), 1 (lane 2), 
10 (lane 3), 100 (lane 4), 500 (lane 5), 1000 (lane 6) or 5000 (lane 7) 
ng plasmid pCG-Hwt and 2 ng reporter plasmid E2-100 CAT. (B) The 
same amounts o f expression and reporter plasmids as in A were used 
and also 5000 (lanes 1 - 3 ) ,  4900 (lane 4). 4500 (lane 5), 4000 (lane 6) 
or 0  (lane 7) ng plasmid pCG-RN was added to transfections to keep 
constant the overall amount o f transfected DNA. (C) Quantitation of 
data from three independent experiments, where Saos2 cells were 
transfected with pCG-Hwt in the presence (empty columns) and absence 
(dotted colum ns) o f plasmid pCG-RN. In the former case, the overall 
amount o f transfected DNA was kept the same (5 |ig). changing the ratio 
o f plasmids pCG-Hwt and pCG-RN in different transfections.
ble in this experiment. Moderate amounts (1 0 -1 0 0  ng) of p53 
expression plasmid lead to promoter activation, whereas higher 
amounts cause loss of this activity. In addition, we transfected 
Cos7 cells wilh plasmid pCG-RN and did not delect transcrip­
tional repression effects similar to those described in Fig. 2 (data 
not shown). Therefore, we believe that the dose-dependent tran­
scriptional effects of p53 protein described in this study are in­
deed causcd by the protein and not nucleic acid sequences.
The results in this study show that the intracellular concen­
tration of p53 per se can be a factor modulating the level of 
expression from promoters regulated by the p53 protein. In addi­
tion to the p53 mutations found in human tumors, which are 
most likely the reason for the loss of cell growth control in hu­
man tumors, one can also predict that overexpression of wild- 
type p53 protein in cells can lead to the abregulation of p53- 
dependent promoters and loss of cell-growth control. It is pos­
sible, therefore, that several human tumors containing the wild- 
type p53 sequence still develop because of defects in p53-dcpen- 
dent pathways.
There are also other proteins in eukaryotic cells that have 
been shown to act as concentration-dependent regulators o f tran­
scription. Low amounts of Krüppel protein led to transcriptional 
activation (Sauer and Jackie, 1991), whereas high levels of 
Krüppel resulted in gene repression (Sauer and Jackie, 1991; 
Licht et al., 1990); both effects were mediated by the same 11- 
bp Kriippel-binding site. Krüppel lacking either the 64 C-termi- 
nal amino acids or the 116 N-terminal amino acids could only 
activate or repress gene transcription showing that different parts 
of the Krüppel protein are essential for gene activation and re­
pression (Sauer and Jäckle, 1991). Similar evidence for the d u al 
function of Hunchback protein have been published, w h ere  con 
centration-dependent activation or repression are m ed ia te d  by 
the same c/.v-acting element (Zuo et al., 1991).
It has been shown that p53 can act as a transactivator of 
transcription from some promoters and as a repressor from oth­
ers (Agol'f et al., 1993; Barak et al., 1993; Chin et al., 1992; 
Deb et al., 1992, 1994; El-Deiry et al., 1993; Jackson et al.. 
1993; Juven et al., 1993; Kastan et al., 1992; Mack et al., 1993; 
Okamoto and Beach, 1994; Ragimov et al., 1993; Subler ct al., 
1992, 1994; Zambetti et al., 1992). Each activity in these cases 
involves a distinct set of cw-acting sequences. In this paper, we 
have shown that p53 can activate or repress transcription from 
the same binding site in a concentration-dependent manner. The 
ability of p53 protein to effect the activation and repression of 
transcription by its interaction with a single binding site provides 
a new aspect for gene regulation in p53-dependent pathways 
using concentration-dependent regulatory mechanisms.
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SH O R T  REPO RT
Oligomerization of p53 is necessary to inhibit its transcriptional 
transactivation property at high protein concentration
Arnold Kristjuhan, Viljar Jaks, Ilvi Rimm, Tiia Tooming and Toivo Maimets
Institute o f Molecular and Cell Biology, Estonian Biocentre. Tartu University, Riia 23. Tartu, EE2400 Estonia
We have previously shown that transactivation by tumor 
suppressor protein p53 can be inhibited in vivo at 
elevated protein concentrations. In this study we 
characterize the structural requirements o f this function. 
We show that oligomerization domain o f p53 is involved 
in loss o f transactivation at high protein concentrations: 
mutants not able to oligomerize are neither able to 
suppress transactivation, although these transactivating 
properties can be untouched.
Keywords: p53; oligom erization; transactivation
Tumor suppressor protein p53 is involved in regulation 
o f transcription activating the promoters located near 
to its D N A  binding sites. Number o f  such genes are 
identified, a part o f  them is clearly involved in 
regulation o f  cell proliferation (Barak et al., 1993; 
Buckbinder et al., 1995; El-Deiry et al., 1993; Kastan et 
al.. 1992; M iyashita and Reed, 1995; Okam oto and 
Beach. 1994; Owen-Shaub et al., 1995). p53 also 
represses many viral and cellular promoters (D eb et 
al.. 1992. 1994; Desaintes et al., 1995; Jackson et al., 
1993; Subler el al., 1992, 1994). Exact mechanism o f  
transrepression is obscure.
For transactivation, p53 must interact with the basal 
transcription machinery and bind sequence-specifically  
to D N A . The corresponding D N A  sequence has been 
characterized having consensus 5 '-R R R C (A /T )(A ; 
T)G Y Y Y N „ ,, R R R C (A /T )(A /T )G Y Y Y -3' (El-Deiry  
et al.. 1992; Funk, et al., 1992).
Several functional dom ains on p53 amino acid chain 
have been characterized. The D N A  binding dom ain o f  
p53 is mapped between amino acids 102 and 290 
(Bargonetti et al., 1993; Pavletich et al., 1993; W ang et 
1993). The N-terminal dom ain o f  p53 (am ino acids 
1 to 42) is needed for transactivation and it interacts 
with basal transcription factors. p53 protein is able to 
form tetramers in vivo, containing the oligom erization  
domain mapped between amino acids 323 and 355 
(Clore er al.. 1994; W ang e t al., 1994). M onomeric p53 
retains transactivating ability (Crook et al., 1994; 
Pellegata et al., 1995; Sang et al., 1994; Tarunina and 
Jenkins. 1993; W ang et al., 1993), but is incompetent 
for transrepression function (Crook et al., 1994; 
Pellegata et al., 1995; Sang et a!., 1994).
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We have previously shown that at elevated 
expression conditions the transactivating property o f  
wt p53 is strongly inhibited. In model systems, lower 
concentrations o f p53 lead to activation o f  a promoter 
containing the consensus D N A  binding site and higher 
concentrations to loss o f  this activity (Kristjuhan and 
Maimets, 1995). The same phenom enon was also  
observed in cell lines where increase o f  endogenous 
p53 was induced with U .V . radiation (Lu e t al., 1996). 
In present study we show that oligom erization is 
necessary for ‘self-inhibition’ o f  transactivation by 
p53.
To study the transactivation properties o f  p53 we 
used a set o f  p53 mutants in CAT assays (Figure la). 
Mutant AI has the first evolutionary conserved 
dom ain o f  p53 deleted (Soussi et a l ,  1990), but it 
behaves similarly to wt protein in transactivation, 
transrepression and growth suppression assays (Crook  
et al., 1994). 1262 contains point m utations in C- 
terminus o f  protein disrupting p53 tetramers into  
monomers (Stürzbecher et al., 1992; Tarunina and 
Jenkins, 1993). M utant Д 3 2 4 -3 5 5  has the oligom er­
ization dom ain o f  p53 deleted. W e controlled  
expression o f  proteins from our constructs in Saos2  
cells, which do not contain endogenous p53 protein. 
All p53 proteins were expressed at com parable levels 
and immunofluorescent staining o f  transfected cells 
showed that all p53 proteins were located in the 
nucleus (data not shown).
The oligom erization dom ain o f  p53 is located 
between amino acids 323 and 355 (Clore et al., 1994; 
Wang et al., 1994). M utants A 3 2 4 -3 5 5  and 1262 were 
expected to be monomers as Д 3 2 4 -3 5 5  has oligom er­
ization dom ain deleted and 1262 contains four point 
mutations which abolish oligom erization o f  p53 
(Stürzbecher et al., 1992). We determined the ability 
o f p53 proteins to form hom ooligom ers in vivo. Saos2  
cells were transfected with p53 expression plasmids and 
lysed 24 h later in IP buffer. Equal am ounts o f  lysate 
were crosslinked with different concentrations o f  
glutaraldehyde and p53 complexes were detected by 
Western blotting. As expected, mutant Д1 and wt 
protein can efficiently form hom odi- and tetramers in 
vivo, while Д 3 2 4 -3 5 5  and 1262 form m onom ers only 
(Figure lb).
To test the ability o f  p53 m utants to activate 
transcription at different concentrations, we cotrans­
fected Saos2 cells with 1 ng  o f  pBS-CO N-C A T reporter 
plasmid and increasing am ounts o f  p53 expression 
plasmids. Cells were collected and lysed 24 h after 
transfection. Before CAT reaction all lysates were 
normalized according to total amount o f  protein and 
efficiency o f  transfection, thus every reaction contained  
the same amount o f  cells positive for p53 expression.
p53 oligomerization and inhibition of transactivation
A Kristjuhan et al
2414
, 3«
I 20 393
4 /--------------
1 32) ЗМ 393
— V —
1
\ V jJ5
b
w t Д| Д324-355 1
1 ' 1 
GA (%) о  о  о  о 0
ГО
£
0
0
1000
- 
ГО
еоо
1000
4324-355
1
Figure 1 Oligomerization o f  p53 proteins, (a) Schematic 
representation o f p53 proteins used in this study. All p53 
cDNA-s were cloned between Xbal and Bgttl sites of eukaryotic 
expression vector pCG  (Tanaka and Herr, 1990). Д1 encodes p53 
with deletion in the first conserved dom ain o f p53 (amino acids 
13- 19). For creating Д 324-355, two regions o f wt p53 cDNA 
were amplified: one between codons 1 and 323 and another 
between codons 356 and 393. Resulting cDNA-s were linked in 
frame to each other from Pstl site designed into PCR primers. 
Half of Pstl site (CAG) encodes an extra amino acid (Glu) 
between these two regions. 1262 contains four point mutations in 
oligomerization dom ain and is described previously (Tarunina 
and Jenkins, 1993). (b) Oligomerization o f p53 mutants. Cells 
transfected with 2 ftg o f p53 expression plasmids, were lysed in IP 
buffer (500 т м  NaCI, 50 т м  Hepes pH 7.5, 1 т м  EDTA, 0.5*/o 
NP40) and crosslinked with different concentrations o f glutar- 
aldehyde. Protein complexes were separated in 6%  S D S -P A A G , 
transferred to nitrocellulose filter and blotted with mixture o f 
antibodies pAb240 and pAbl801. Concentration o f glutaralde- 
hyde (GA) is indicated on top o f lanes. Bands corresponding to 
mono-, di- and tetramers are indicated on left side (I, 2 and 4, 
respectively)
As expected, the highest activation o f  reporter gene by 
wt p53 was observed in transfections with relatively 
low concentration o f  expression plasmid (Figure 2a), 
while increasing am ounts o f expression plasmid caused 
decrease in CAT activity.
M D M 2 protein can inactivate transactivation 
capability o f  p53 interacting with transactivation 
dom ain o f  p53 and directing its degradation (Haupt 
et al., 1997; Kubbutat et al., 1997). Transcription o f  
M D M 2 gene is activated in p53 dependent manner 
(Barak e t al., 1993). Therefore it is possible that high 
expression o f  p53 protein causes accumulation o f  
M D M 2 protein, which in turn inactivates p53. To  
avoid effects o f  M D M 2 protein we used the p53 AI 
mutant, which has M D M 2 binding domain deleted and 
is resistant to M DM 2-dependent inactivation and 
degradation (Kubbutat e t al., 1997). Deletion o f  the
first evolutionarily conserved dom ain o f p53 caused 
decrease in the absolute level o f  reporter activation, but 
overall pattern o f transactivation was the same; at 
higher amounts o f  expression plasmid the CAT activity 
was inhibited (Figure 2b). A t the same time activations 
of reporter gene by monomeric p53 mutants A 3 2 4 -3 5 5  
and 1262 were not inhibited at higher concentrations o f  
expression plasmid and CAT activity reached to 
plateau (Figure 2c and d). The loss o f  self-inhibition  
is likely to intrinsic property o f monomeric p53 as 
results with both monomeric p53 mutants (deletion and 
point mutant) were similar. A s a negative control we 
used the Hisl 75 point mutant, which did not activate 
reporter gene at any concentration (data not shown).
The expression vector pCG contains strong eukar­
yotic promoter (cytom egalovirus immediate early 
promoter) able to bind cellular proteins essential for 
transcription. Therefore one could argue that high 
amount o f  pCG vector itself can be responsible for 
repression o f  transcription from other promoters. 
However, since all p53 proteins were expressed from 
the same type o f  vector, the results from CAT assays 
with Д 3 2 4 -3 5 5  and 1262 proteins show that decrease 
o f  CAT activity by wt and Д1 proteins is not caused by 
high level o f  pCG plasmid itself. While wt and AI 
proteins can activate reporter gene already at very low  
concentrations (1 and 10 ng o f  expression plasmid), 
monomeric p53 mutants A 3 2 4 -3 5 5  and 1262 had no 
detectable activation at less than 100 ng o f  expression 
plasmid used. It can reflect the decreased D N A  
binding activity o f  m onom eric proteins.
To be sure that all p53 mutants were expressed at 
comparable levels and cover the same ranges o f  
concentrations we defined the relative amount o f  p53 
in all lysates used for CAT assays. Transfected cells 
were collected 24 h after transfection and divided 
between two tubes. H alf o f  cells was lysed for CAT  
assay, the second half was lysed for Western blotting 
directly in SDS loading buffer. All protein lysates were 
separated in S D S -P A G E  at the same time and 
transferred to the same piece o f  P V D F membrane. 
The membrane was incubated with mixture o f  primary 
antibodies against p53 (рАЫ 801 and pAb240) and 
against TBP (3G3). After incubation with biotinylated 
secondary antibody and avidin-FITC, fluorescent 
signal was quantitated with Fluorlm ager and Image- 
Q uaN T software. 43 kD  band o f  TBP can be easily 
separated from p53 bands and was used as internal 
standard for determination o f  total am ount o f  protein. 
Ratio between signals from p53 and TBP bands was 
further divided with percentage o f  transfection 
efficiency o f  particular series o f  transfection. Result is 
given on Figure 3 and reflects ratio between signals o f  
p53 and TBP bands per transfected cell. This result can 
be used only for comparison o f  protein amount on 
different lanes o f  the same blot and can not be 
interpreted as intracellular molar ratio between p53 
and TBP, because the latter depends on concentration 
and affinity o f  different antibodies. As seen on Figure 
3, the same amount o f  expression plasmid produced 
roughly the same amount o f  different p53 proteins and 
amount o f  each protein correlated with am ount o f  
expression plasmid used in transfections. Exception 
was AI, which had higher steady-state level at every 
concentration point. Diminished degradation can be 
reason for elevated level o f  AI protein, which has been
p53 oligomerization and inhibition of transactivation
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Figure 2 Activation o f transcription by p53 proteins al different concentrations. Saos2 cells were cotransfected with I ;<g o f CAT 
reporter plasmid and different am ounts of p53 expression plasmids and were lysed 24 h alter transfection. All lysates were 
normalized before CA T reaction according to total am ount of protein (Bradford. 1976) and efficiency o f transfection, thus every 
reaction contained the same am ount o f  transfected cells. Three independent series o f CAT assays with each p53 construct were 
quantitated with Phosphorlm ager and Im ageQ uaN T software, (a) wt p53: (b) Д1: (с) Д324 355; (d) 1262. The am ount o f p53 
expression plasmid is indicated on abscissa o f  each diagram  (in nanograms). The ordinate shows the percentage o f chloramphenicol 
acetylalion. S tandard e rro r is indicated by error bars. CAT reporter plasmid contains the Д7;«1-Л7«/1 fragment from plasmid E2- 
100 CAT (Tarunina and Jenkins. 1993) in pBluescript K.S". It has p53 consensus DN A-binding site CON (Funk et at.. 1992) and 
modified adenovirus E2 prom oter in front o f  chloramphenicol acetvltransferase gene. Efficiency of transfection was determined by 
parallel transfection with /(-galactosidase expression plasmid pON26() (Sp.ietc and M ocarski. 1985)
shown to be resistant to M DM 2-directed degradation  
and is more stable when expressed in cells (Kubbutat 
and Vousden. 1997: Kubbutat et al., 1997). Quantita­
tion o f  proteins also shows that weak activation o f  
reporter gene by Д1 is not caused by lack o f  protein 
expression.
To test whether changes in specific D N A  binding 
activity o f  p53 are responsible for loss o f  transactiva­
tion at high expression level, we tested the D N A - 
binding properties o f  wt p53 expressed at different 
concentrations. As seen on Figure 4, amount o f  specific 
D N A  bound to wt p53 correlates with am ount o f p53 
expression plasmid used in transfections indicating that 
low transactivating activity o f  p53 is not caused merely 
by low proportion o f  functional protein in the pool 
(compare CA T activity on Figure 2a and D N A -binding  
activity on Figure 4 lines 1 to 6). Retarded band seen 
on Figure 4 is specific to p53 because it can be titrated 
out with 25-fold molar excess o f  unlabelled CON site
but not with nonspecific oligonucleotide (Figure 4, lines 
6 to 8). It also can be supershifted with p Ab 1801 
antibody reacting with N-terminus o f  p53 but not with 
pAb419 antibody directed against SV40 large T antigen 
(Figure 4, lines 4. 9. 10). p A b l80 l does not produce 
any bands when cell lysate does not contain p53 
(Figure 4. line 11).
Previous studies have shown that expression level 
can be a factor modulating the transactivating proper­
ties o f  p53. p53 accum ulates efficiently after U.V. 
induction in mouse N1H3T3 and T22 cells. It has. 
however, been demonstrated that there is a discordance 
between the transcriptional activity o f  p53 and its 
protein level: expression o f  p53 target genes is induced 
only in cells, which contain moderate level o f  p53 
protein and no gene expression is observed at high 
protein concentration (Lu et «/., 1996). We have shown 
with reporter systems that the transactivation cap­
ability o f  wt p53 is strongly inhibited by high protein
p53 oligomerization and inhibition of transactivation
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Figure 3 Q uantitation o f relative am ount o f p53 proteins. 
A m ount of p53 protein was determined in every transfection. 
Fluorescent signal from p53 and TBP bands of W estern blot were 
quantitated with Fluorlm ager. D iagram  shows ratio between p53 
and TBP bands per transfected cell (ordinate) at different 
am ounts оГ expression plasmid used in transfections (abscissa). 
Columns show the average value, e rro r bars indicate standard 
error. Cells were lysed 24 h after transfection in SDS loading 
buffer (50 т м  Tris-HCI pH  6.8; 100 т м  DTT; 2%  SDS; 0 1% 
brom ophenol blue; 10% glycerol) and boiled for 10 min. Lysate 
was separated by S D S -P A G E  in 10% gel. Proteins were 
transferred to  BioBlol-PVDF m em brane (‘C ostar’). Free surface 
of the filter was blocked for 10 min at R T  with 1% non-fat milk 
powder in P B S +  0.05% Tween 20. M embrane was incubated with 
monoclonal antibodies 3G3, pA bl80 l and pAb240 in blocking 
solution for 2 h at RT. After washing with PBS +  Tween 20, filter 
was incubated for 1 h at RT with biotinylated secondary antibody 
against mouse Ig. Finally, the m em brane was incubated with 
streptavidin-FITC. Q uantitation of data  was performed with 
Flourlm ager and Im ageQuaN T software (‘M olecular Dynamics')
concentration in the cells (Kristjuhan and M aimets,
1995). In this study we specified the structural 
requirements o f  this finding. W e showed that 
oligom erization o f  p53 protein is needed for loss o f  
transactivation at high p53 concentrations. The highest 
transactivating activity o f  oligom erization-com petent 
wt and Д1 proteins was observed at relatively low  
concentrations o f  p53 protein. Increasing p53 concen­
tration causes inhibition o f  transactivation when 
compared with lower protein amounts. This effect 
was not observed with m onom eric p53 proteins. W e 
also tested p53 m utant 517 (Tarunina and Jenkins,
1993), which forms preferably dimers but also higher 
oligom ers in solution (Stürzbecher et al., 1992). The 
level and dynamics o f  transactivation by 517 was the 
same as with wt p53 (data not shown). We conclude 
that oligom erization o f  p53 is important to suppress 
transactivation at high concentrations.
M echanism  o f transactivation by p53 is m ost likely 
based on interactions with proteins o f  the basal 
transcription machinery. T o date it has been shown  
that p53 interacts with T FIIH  and T FIID  com plexes 
(Liu et al., 1993; X iao et al., 1994), with TBP (M artin 
et al., 1993; Seto et al., 1992; Truant et al., 1993), 
TBP associated proteins TAF„60 and TA F„40 from  
Drosophila  cells (Thut et al., 1995), and with human 
analogue o f  Drosophila  T A F It40, TAFn31 (Lu and 
Levine, 1995). At overexpression conditions, activator 
proteins could titrate out som e basal transcription
1 2 3 4 5 6 7 8 9  10 11
Figure 4 D N A binding activity o f wt p53 at different 
concentrations. Lysates from  cells transfected with different 
am ounts o f  pCG -H w t were incubated with 2 ng o f radiolabeled 
CO N  site in buffer containing 20 т м  HEPES pH  7.5, 100 т м  
NaCl, I т м  M gClj, 0.1%  NP40, 5% sucrose, 200 ng herring 
sperm D N A and 2 ц\ рАЬ421 supernatant. A m ount o f  expression 
plasmid used for transfection is indicated on top  o f lanes. 50 ng 
o f unlabeled CO N site or nonspecific ds-oligonucleotide was 
added to reactions on lanes 7 o r 8, respectively. Five ц\ o f 
pA bl 801 or pAb419 supernatant was added as indicated. Protem- 
DNA complexes were separated in 5% TBE polyacrylamide gel 
and exposed to X-ray film
factors, am ount o f  which is limited in the cell. This 
phenom enon is known as squelching (Ptashne, 1988). 
A t optim al concentrations, every activator m olecule 
bound to the test prom oter, is also bound to the 
target molecule(s) (for example T F IID  com plex). In 
excess o f  the activator, m ost o f  activator proteins 
bound to the test promoter are not bound to the 
target m olecule(s) because o f  limited am ount o f  the 
latter. Therefore, activation o f  the test promoter is 
inhibited as com pared to the optim al concentration o f  
activator. In the case o f  p53, in vitro  experiments have 
shown that T F IID  com plex and TFIIB protein are the 
limiting factors, which can be titrated out by excess 
am ounts o f  p53 (Liu and Berk, 1995). It is therefore 
possible that inhibition o f  transactivation by wt and 
AI proteins at high concentrations is caused bv 
squelching o f  som e basal transcription factors. On 
the other hand, high levels o f  m onom eric mutants 
Д 3 2 4 -3 5 5  and 1262 did not cause the effect o f  
squelching.
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One possible explanation here is that monomeric 
p53 can not interact with transcription machinery at all 
and therefore it can not squelch basal transcription 
factors. A nalogously, oligom eric state o f  p53 is needed 
for interaction with M D M 2 (M arston e t al., 1995). 
A lthough specific com plex between D N A  and m ono­
meric p53 is poorly detectable in cell lysate, purified 
p53 monomers are capable to bind cooperatively to 
consensus D N A  (Balagurum oorthy et al., 1995; W ang 
et al., 1995). p53 binding D N A  consensus sequence 
contains two tandem decameric elements, each contain­
ing two pentameric inverted repeats. Therefore, the 
D N A  itself can be a factor, which brings four p53 
m onomers together and p53 could gain the ability to  
interact with transcription machinery only after 
binding to the D N A  consensus sequence. Increasing 
concentration o f  m onom eric p53 in the cell could  
increase probability that more test promoters are 
bound to multiple p53 monom ers, which in tum  
assures higher transcription efficiency from the 
promoter.
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Tumour associated mutants of p53 can inhibit transcriptional activity of p53 
without heterooligomerization
A Jõers, A Kristjuhan, L Kadaja and T Maimets
Department o f Cell Biology, Institute o f  Molecular and Cell Biology, Tartu University, Riia 23, Tartu EE2400. Estonia
Tumour suppressor protein p53 is the m ost frequent 
target o f mutations occurring in different types o f human 
cancers. M ost o f these are point mutations clustered in 
certain ‘hot spots’. Because p53 is a tetramer in solution, 
it can form heterooligomers when both wild-type and 
mutant forms o f p53 are expressed in the same cell. 
Inactivation o f  wt p53 by heterooligomerization has been 
proposed as a mechanism for dominant negative effect o f 
mutant protein. In this paper we show that other 
mechanisms can also be involved in the inhibition of 
transcriptional activity o f wt p53 by mutant proteins. In 
addition to suppressing the wt p53 activity, mutant 
proteins are also able to suppress the activity o f p53 
protein unable to oligomerize. Either N - or C-terminus 
of mutant p53 are needed for this activity. The 
suppression o f  transcriptional activity described is 
restricted to p53-dependent promoters and no effect is 
seen with the promoter not containing p53 binding site. 
Point mutants also inhibit the growth suppressing 
activity o f monomeric p53. Our data allow to propose 
the existence o f  a cofactor specifically needed for p53- 
dependent transcription. Depletion o f  this cofactor could 
be an alternative mechanism o f inactivation o f  wt p53 by 
its point mutants.
Keywords: p53; transcription; oligom erization
Introduction
Tumour suppressor protein p53 has been show n to be 
involved, either directly or indirectly, in m any cellular 
activities. It controls transcriptional activation from 
promoters contain ing its binding site (Funk et al., 
1992; E l-Deiry e t al., 1992) and the translation o f  its 
own m R N A  (M osner et al., 1995). p53 also has direct 
effect on D N A  replication in em bryonic cells (Cox et 
al., 1995). It is involved in the control o f  cell cycle 
(Levine et al., 1991) and apoptosis (Low e e t al., 1993).
O f all these activities, the regulation o f  transcription 
by p53 has been m ost extensively studied. p53 binds 
specifically to  D N A  similar or identical to the 
consensus 5 'R R R C (A /D (A /T )G Y Y Y N 0-,jR R R C (A / 
T)(A /T)G Y Y Y 3'(E1-D eiry et a l ,  1992). There are 
several genes containing this type o f  p53 binding site 
in their prom oters and are therefore regulated by 
changes o f  levels o f  p53. These include p 2 1 WAF1'C1I>I (Hl- 
Deiry et al., 1993), mdm2 (Barak et al., 1993), gadd45 
(Kastan et al., 1992), bax (M iyashita and Reed, 1995) 
and IG F BP-3 (Buckbinder et al., 1995).
Hum an p53 protein, which contains 393 am ino acids, 
is able to form  tetramers due to the protein-protein 
interactions. A n area responsible for tetramerisation is 
located between am ino acids 323 and 355 (C lore et al., 
1994; W ang e t al., 1994). It has been show n that 
oligom eric p53 is m ore active in transcription, but 
m onom eric form s o f  p53 are also able to  activate 
promoters contain ing p53 binding site (Tarunina and 
Jenkins, 1993; W ang e t al., 1993; C rook e t al., 1994; 
Sang et al., 1994; Pellegata e t al., 1995). Although  
m onom eric p53 does not form oligom ers in solution, it 
still binds D N A  co-operatively as a tetramer (Balagur- 
um oorthy et al., 1995).
In human tum ours p53 protein has been often 
mutated. Because it is expressed from  both  alleles, the 
overall content o f  intracellular p53 can be either wild- 
type (wt), m ixture o f  wt and m utant p53 or m utant p53 
only (when both  alleles are m utated or one allele is 
deleted). A lthough the tum our-associated mutations 
found cover the w hole m olecule, certain ‘h o t spots’ for 
m utations have been described (Levine e t al., 1991). 
These point m utants have lost their D N A -binding  
activity. In the case o f  coexpression o f  m utant and wt 
p53 it has been show n that m utant p53 can drive wt 
p53 to m utant conform ation (M ilner and M edcalf, 
1991) and the transactivation function o f  w t p53 is 
inhibited by m utant p53 (K ern et al., 1992). It is 
generally believed that the m echanism  behind this effect 
is that m utant p53 proteins form  heterooligom ers with 
wt proteins, w hich are less active in transcriptional 
activation than hom ooligom ers o f  w t protein.
In this paper we show  that, in addition o f  
heterooligom erization, other m echanism s o f  repression 
o f  p53 function can also be involved in cells expressing 
both wild-type and mutant p53. W e show  that (1) the 
transcativation function o f  p53 protein unable to 
oligom erize is also suppressed by tum our-associated  
m utants o f  p53; (2) This effect is specific to p53- 
dependent prom oters and requires the presence o f 
either C- or N -term inus o f  the m utant protein; (3) 
Tum our-associated point m utants are able to inhibit 
the growth suppressing function o f  m onom eric p53. 
Our data allow  to propose the existence o f  p53-specific 
transcriptional coactivator(s) needed for p53 to activate 
the p53-specific promoters and m ediate its biological 
effects.
Results
Tum our-associated poin t m utants o f  p53 can inhibit the 
transactivation function  o f  monom eric p53
Correspondence: T M aim eis M utant p53 has a dom inant negative effect over the wt
Received 14 July 1997; revised 26 M ay 1993; accepted 26 M ay 1998 protein. This is thought to be m ediated through the
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hctcrooligom crization between wt and mutant p53. In 
that case, the m onom eric p53 would be insensitive to 
mutant protein, because heterooligom crs cannot form. 
To test this hypothesis, we carried out series o f  
transfcctions (Figure 2). Every transfection contained
1.2 /jg o f  pB S-C O N -C A T  as a reporter and 250 ng o f  
A 3 2 4 -3 5 5  as a transactivator (except the first column, 
which represents transfection, containing only the 
reporter). Cells were lysed after 24 h and CAT assays 
were performed. Cotransfection with different point 
mutants clearly inhibited the activity o f  Л 324-355  
(Figure 2a). To get m ore insight into the nature o f  this 
inhibition, we m ade several deletions based on the 
Trp248 m utant (Figure 1). W hen either N - or C- 
terminus are deleted, the m utant can still inhibit the 
transcriptional activity o f  the Д 3 2 4 -3 5 5  (Figure 2B). 
When both o f  these termini are absent (40-361Trp), the 
mutant is not able to  repress the Д 3 2 4 -3 5 5  activity. 
Neither o f  the point m utants used had any transcrip­
tional activation function by them selves (data not 
shown).
Repression phenomenon is not dependent on the nature 
o f  the p53 binding site
Reporter plasm id, used in the experiments described in 
Figures 2a and b, contains a synthetic p53 binding site 
in front o f  the adenovirus E2 prom oter. This binding  
site, named C O N , binds p53 very efficiently and does  
not occur in natural prom oters. To test our finding in 
more physiological context, w e did the same kind o f  
experiments using a plasmid pW W P-C A T, containing  
2.4 kb fragment from  hum an W AF1 prom oter in front 
of the CAT gene (El-D eiry et al., 1993). Figure 3 shows 
the results o f three independent experiments. Every 
transfection contained 1.2 pg  o f  pW W P-CAT as a 
reporter and 5 p g  o f  p C G -A 3 2 4 -3 5 5  as a transacti­
vator (except the first colum n, were only  the reporter 
plasmid was used for transfection). N o te  that we used 
much higher am ount o f  p C G -Ä 3 2 4 -3 5 5  than in 
previous experim ent in order to get sufficiently high 
CAT activity. T his was probably due to weaker 
binding o f  p53 to its binding site in W AF1 promoter 
as com pared to the C O N  site. Different point mutants
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Figure 1 Schematic representation o f  deletion m utants o f p53. 
Asterisks indicate point m utations. Functional domains And 
epitopes for antibodies are indicated
repress the transactivation function o f  the Д 3 2 4 -3 5 5  
with the sam e pattern as in the Figures 2a and b -  
only the 40-361Trp m utant was not able to inhibit the
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Figure 2 M u tan t р53 proteins inhibit transactivation of 
monomeric p53. (a) Cells were cotransfected with Д 324-355 
(250 ng) p53 expression vector and with expression plasmid 
carrying point m utant p53 cD N A  or with em pty pCG  plasmid 
(5 jig). 1.2 /ig o f  pBS-CON-CA T reporter plasm id was included in 
every transfection. Colum ns indicate average C A T  activity from 
three independent experiments. CA T activity from  cotransfection 
with empty pC G  vector is taken  as 1. (b) Cells were cotransfected 
with Д 324-355  (250 ng) p53 expression vector and with the 
expression plasm id carrying deletions o f  Trp248 m utant (5 fi%) 
1.2 j/g o f  C A T reporter plasm id was included in every 
transfection. Colum ns indicate average CA T activity from three 
independent experiments. C A T  activity from cotransfection with 
empty pCG  vector is taken as 1
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transcription. W c also used a reporter with p53 binding 
site from m dm 2 prom oter and this also behaved 
similarly (data not show n). W c concludc that 
inhibition o f  transactivation function o f  m onom eric 
p53 by point m utant occurs from  different p53 binding 
sites and does not depend on prom oter structure.
p5>-independent transcription is not affected by point 
mutants
Wt p53 can, at least when overexpressed, inhibit many 
different prom oters. T hough there are no hints in the 
literature that tum our-associated point m utants can do 
the same, we tested their ability  to inhibit the CM V  
promoter. This is a strong eukaryotic promoter, 
containing no p53 binding sites. A  plasm id, containing  
ß-galactosidase gene under the control o f  CM V  
promoter w as included in every transfection. After 
the. lysis o f  the cells h a lf o f  lysate w as used to 
determine the /?-galactosidase activity. A s the Figure 
4 shows, tum our associated poin t m utants do not affect 
the /J-galactosidase activity. Therefore, the inhibitory 
effect o f  the point m utants is restricted to the 
promoters contain ing p53 b inding site.
Coexpression o f  po in t m utants w ith A 3 2 4 -3 5 5  does not 
alter the quan tity  or localisation o f  the la tter
One possibility to  explain w hy the poin t mutants 
inhibit the activity o f  the A 3 2 4 -3 5 5 , is that their own  
expression m ay saturate som e stage o f  the gene 
expression and therefore the expression o f  the Д 3 2 4 -  
355 decreases. T o  control this, we analysed by western 
blotting the lysates from cells contransfected with 
A 3 2 4 -3 5 5  and different point m utants (Figure 5). N o  
remarkable differences in the am ount o f  Д 3 2 4 -3 5 5  can 
be observed between different transfections. Therefore,
Figure 3 Inhibition o f  transactivation  occurs also from  natural 
prom oters. Cells were co transfected  with Д 32 4 -3 5 5  (5 ц%) p53 
expression vector and w ith expression plasmid carrying point 
m utan t p53 cD N A , deletions o f  Trp248 m utant or with empty 
pCG  plasm id (5 ^g). 1.2 o f pW W P-C A T reporter plasmid was 
included in every transfection. C olum ns indicate average CAT 
activity from  three independent experim ents. CA T activity from 
cotransfcction  w ith em pty  p C G  vector is taken a s  1
2 0
the differences in the transcriptional inhibition function 
between A N 39Trp and 40-361T ip  or between 
AC362Trp and 40-36 ITrp can not be explained by 
different expression levels o f  A 3 2 4 -3 5 5 . N o te  that 
AC362Trp and A 3 2 4 -3 5 5  com igrate as a one band.
In order to function as transcriptional activator p53 
must be localised in cell nucleus. It could be possible 
that expression o f  the poin t m utants will abolish the 
nuclear localisation o f  the A 3 2 4 -3 5 5 . To control this 
wc cotransfected the cells cotransfections with pCG  
Д 3 2 4 -3 5 5  and with plasm ids encoding deletions o f  
point mutants. Im m unoflorcscence analysis with 
different antibodies detected only the A 3 2 4 -3 5 5
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Figure 4 Point m utan t p53 p ro te ins do  not inhibit p53- 
independent transcription. All transfections, were Д 324-355  was 
used as activator, contained 0.5 >jg o f  Д-galactosidase reporter 
plasmid with C M V  prom oter. C olum ns indicate average ß- 
galactosidase activity from  th ree independent experiments. 
Activity from  cotransfection w ith  em pty pC G  vector is taken as 1
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Figure 5 Coexpression with different deletion m utants does not 
alter the am ount o f  Д 32 4 -3 5 5 . Cells weTe cotransfected with 5 pg 
pC G -Ä 324-355 and with 5 //g o f the constructs indicated. After 
24 h cells were lyscd and the W estern blot was carried oui. p53 
was detected w ith m onoclonal an tibody  pAb240
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protein in cclls expressing two form s o f  p53. As shown 
in Figure 6, the Д 3 2 4 -3 5 5  is nuclear in all cases 
examined and the inability to localise in nucleus is not 
the reason for transcriptional inhibition.
A324 -  355 does not fo rm  heterooligomers with p53 point 
mutants
T o show  that protein A 3 2 4 -3 5 5  is not able to give 
oligom ers in  the expression conditions used here we 
carried out crosslinking experiments. Cells cotrans­
fected with Д 3 2 4 -3 5 5  and m utants AN39Trp, 
AC362Trp or 4 0 -3 6 ITrp were lysed, crosslinked with 
glutaraldehyde, devided between tw o equally loaded  
gels, electrophoresed and blotted to nitrocellulose. 
U sing different primary antibodies we were able to 
show that even in the case o f  coexpression with point 
mutant the A 3 2 4 -3 5 5  remains m onom eric in solution  
(Figure 7). From  this we conclude that transcriptional 
inhibition by A N 39Trp and AC362Trp is not due to 
heterooligom erization with Д 3 2 4 -3 5 5 .
Point m utants can inhibit the growth suppression  
function o f  m onom eric p53
In order to  clarify the relevance o f  our results in more 
biological assay, w e tested the influence o f  point 
mutants to the growth suppression activity o f Д 3 2 4 -  
355. It is reported that m onom eric p53 expresses clear 
growth suppressing activity, although less than wt 
protein does (Shaulian et al., 1993; T hom as et al., 
1996). W e perform ed growth suppression assay and 
results o f  that are described in Figure 8. W t p53 
inhibited co lony  form ation alm ost entirely and Д 3 2 4 -  
355 reduced the number o f  colonies approxim ately  
50% as com pared to the transfections with the 
resistance marker (pBabe Puro) only. W hen Trp248, 
AN39Trp or AC362Trp were added to the transfection 
mixture, they inhibited the growth suppressing activity 
o f the m onom er. The same m utants did not affect 
notably the colony form ation activity, w hen expressed 
alone with pB abe Puro (data n o t show n). Because the 
40-36ITrp has itself the ability to reduce the colony  
number (data not show n), its effect to the activity o f  
the m onom er could not be exam ined.
Discussion
Transcriptional activation is the best studied biochem ­
ical function o f  p53. p53 m ediates signals for cell cycle 
arrest and apoptosis by activating transcription from  
m any different prom oters (K astan et al., 1992; El-Deiry  
et al., 1993; Barak et al., 1993; M iyashita and Reed, 
1995; Buckbinder e t al., 1995). T um our hot-spot 
m utations occur at residues essential for D N A -binding  
and therefore inactivate the transcriptional activation  
function o f  p53 (Kern et al., 1992). Because m ost o f  wt 
p53 exists in tetrameric form, heterooligom ers between  
wt and m utant p53 are present in tum ours. Inactiva­
tion o f  wt p53 by heterooligom erization with mutant 
protein is thought to be the m echanism  o f  inhibition o f  
wt p53 activities by m utant p53, transcriptional 
activation included. However, we present here experi­
mental evidence showing that hcterooligom erization is 
not the only w ay how  mutant p53 can inhibit wt p53
A
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Figure 6 Д 324-355  is nuclear when coexpressed with point 
m utants. Cells were transfected with the 5 /jg pCG -A N 39Trp (a), 
pCG-A C362Trp (b) o r pCG-40-361 T rp  (c). 5 fig pC G -A 324-355 
was included in all transfections. In  a and с cells were stained 
with antibody В17, which reacts with p53 am ino acids 16-25 
(epitope deleted in AN 39Trp and in 40-36lTrp). In b cells were 
stained with an tibody pAb421, which reacts with p53 amino acids 
3 7 2 -3 8 2  (epitope deleted in ДСЗб2Тгр). W ith these antibodies 
only the Д 324-355  is detected. Transfection efficiency was 
approxim ately 25%
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Figure 7 Д 3 2 4 -3 5 5  d o es not form heterooligom ers with point 
m utants. Cells were transfected w ith  2 fig  p C G -A N 39T rp  (a), 
pC G -A C 362T rp (b) or p C G -40-361T rp  (c). 2 jig p C G -A 3 2 4 -3 5 5  
was included in all transfections. C ells were lysed and proteins  
crosslinked w ith  glutaraldehyde as described in M aterials and  
m ethods. E very sam p le w as divided in tw o, electrophoresed  and
transactivation function. M utant forms o f  p53 can also 
inhibit the transactivation function o f  m onom eric p53 
(Д 3 2 4 -3 5 5 ; Figure 2, sec also Subler e t al., 1994). 
W hen both N - and C-termini are deleted from mutant 
p53, it is not able to inhibit Д 3 2 4 -3 5 5  (Figure 3). The 
p roof that point m utants can also affect the biological 
activity o f  the m onom eric p53 com es from growth 
suppression assay (Figure 8). Expressing point mutants 
together with Д 3 2 4 -3 5 5  clearly inhibited the growth 
suppression function o f  the latter. Taken together, our 
data suggest that in addition to heterooligom erization  
also other m echanism s can stay behind the inhibition  
o f w t p53 by its m utant forms.
A s a transcriptional activator p53 needs to bind 
several basic transcription factors. Indeed, interactions 
between p53 and com ponents o f  T F IID  and TFIIH  
com plexes have been described (Liu et ah, 1993; Lu 
and Levine, 1995; Martin et al., 1993; Selo et a l 1992; 
Thut et al., 1995; Truant et al., 1993; X iao et al 1994) 
It could be possible that m utant p53 binds some ol 
these basic factors and depletes the cells from them. 
Our results show  that this is not the case: over­
expression o f  m utant p53 does not alter the expression 
from  CM V prom oter (Figure 4), activity o f  which is 
also dependent on general transcription factors. Over­
expression o f  m utant p53 has influence only to  p53- 
dependent prom oter and this is not caused by 
alterations in Д 3 2 4 -3 5 5  expression or localisation
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Figure 8 Point m utants can inhibit the growth suppression 
function o f  the Д324-355. Cells were cotransfected with pBabe 
Puro (2 fig; contains the p u ro tn y d n  resistance gene between 
M uLV LTRs), pCG -A 324-355 (5 fig', except colum n 1 and 2) and 
w ith S fig o f plasm ids encoding proteins indicated on  graph. 
Twenty-four hours after transfection cells were replated (1.5 x 106 
cells per plate); selection period for puromycin resistant colonies 
was 2 weeks. Colum ns indicate the relative am ount o f  colonies 
(pBabe Puro only =  1; average o f  three independent experiments)
blotted on nitrocellulose. A ntibodies pAb240 and рАЫ801 were 
used to detect all forms of p53. In  duplicate lanes, the antibody 
recognising only the Д 324-355  was used (a B17; b and с 
рАЬ421). Bands corresponding to  m ono-, di- and  tetram ers are 
indicated on left side ( I, 2 and 4, respectively)
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(Figures 5 and 6). From these data we propose that 
mutant p53 interacts with factor(s) specifically needed 
for p53-dependent transactivation but not for tran­
scription in general.
M ost tum our-associated mutations in p53 are 
clustered in the central part o f  the m olecule and they 
inactivate the D N A  binding function o f  the p53. Som e 
o f these m utations affect the overall conform ation o f  
central part o f  the molecule (G annon et a l ,  1990), 
whereas conform ations o f  the N - and C-termini arc 
m ost probably not changed. Therefore, the m odifying 
enzymes and cofactors targeted to the termini o f  wt 
molecule are also able to bind to m utant p53. If the 
mutant form o f  p53 is expressed at high level, it may  
deplete cells from  cofactors, necessary for p53 to  
activate transcription. The transactivating function o f  
p53 can be allosterically m odified by different factors. 
It has been show n that D N A -bin ding o f  w t p53 can be 
enhanced by specific peptides and antibodies against 
the C-terminus (H upp e t al., 1992, 1995). The c-Abl 
and WT-1 are cellular proteins binding w t p53 and 
activating its transactivation function (G oga e t al., 
1995; M aheswaran e t al., 1993, 1995; Yuan et al.,
1996). Recently, new activators o f  p53 were identified, 
including ref-1 (Jayaraman et al., 1997), HM G-1 
(Jayaraman et al., 1998), p33,NO‘ (G arkavtsev et al., 
1998) and BRCA1 (Ouchi et al., 1998; Zhang e t al., 
1998). It is not known, whether they can interact with 
point m utants o f  p53 or with m onom eric p53. 
Therefore we have no clues to speculate, could one  
o f  these activators be depleted from  cells by mutant 
p53 in our experiments. N ecessity o f  coactivator for 
p53-dependent transactivation is show n only for 
p33,N01. W hether the others are also necessary for 
p53-dependent transactivation or have only  additive 
effects needs to be clarified in future.
T w o explanations can be proposed to  the fact that 
40-361 Trp cannot inhibit Д 3 2 4 -3 5 5  mediated 
transactivation. First, the deletions o f  both ends in 
40-361 Trp m ay affect the overall conform ation  o f  the 
m olecule m aking it unable to bind the specific cofactor. 
The other explanation com es from  hypothesis accord­
ing to which N - and C-termini are close to  each other 
in 3-dim ensional structure. They could  generate a 
binding site for this proposed cofactor and only the 
deletions o f  both o f  them abolish the binding o f  the 
cofactor.
A lternatively, wt p53 may need a specific m odifica­
tion for its activity rather than binding to a specific 
cofactor. Indeed, many kinases have been shown to 
phosph.orylate p53. Casein kinase II and protein kinase 
С phosphorylate the C-terminus o f  p53 and probably 
unmask the D N A -bin ding function o f  p53 (Baudier et 
a l ,  1992; Takenaka et a l ,  1995; M eek e t a l ,  1990). S 
and G j/M  cdks can also activate p53 and even 
influence its binding site specificity (W ang and Prives, 
1995). In addition to С-terminal phosphorylation sites, 
m any serine residues which can be phosphorylated are 
clustered in N-term inus (M ilne et a l ,  1992; Knippchild 
et a l ,  1996; Lees-M iller et al., 1992). Replacing two or 
more o f  these serine residues with alanines diminishes 
p53 transactivating abilities (M ayr e t a l ,  1995). It is 
also know n that wt p53 purified from  bacteria does not 
bind D N A , although p53 produced in insect or 
mam m alian cells does (H upp et a l ,  1992; W olkowicz  
et a l ,  1995). Possible explanation for this is that wt p53
from bacteria does not have ncccssary modifications. If 
p53 needs to be phosphorylated in order to  activate 
transcription, the inhibitory effect o f  point mutants to 
Д 3 2 4 -3 5 5  mediated transcription m ay relay on the 
saturation o f  the m odifying enzym es. Bccausc point 
m utants arc expressed in high am ounts they could 
titrate the Д 3 2 4 -3 5 5  out. Follow ing this line two or 
more m odifications are needed for transactivation by 
p53 -  at least one for N - and the other for C-terminus. 
If even one o f  these possible m odifying enzymes is 
depleted from  wt p53, the p53 cannot activate 
transcription. Only in the case o f  40-361 Trp the 
Д324-355 retains its activity, because this deletion o f  
point m utant is not able to  bind any modifying 
enzyme.
Materials and methods 
Plasmid constructs and antibodies
CAT reporter plasmid pBS-CON-CAT contains the Xhol -  
Xbal fragment from plasmid E2-100 CAT (Tarunina and 
Jenkins, 1993) in pBluescript KS~. It has p53 consensus 
DNA-binding site CON (Funk et a l ,  1992) and modified 
adenovirus E2 promoter in front o f  CAT gene. pWWP- 
CAT contains 2.4 kb region from human WAF1 promoter 
(El-Deiry et a l ,  1993) in front o f the CAT gene and was a 
generous gift from Dr. Bert Vogelstein. Plasmid pON 260 
(Spaete and Mocarski, 1985) was used to express ß- 
galactosidase from CMV promoter. pBabe Puro contains 
the puromycin resistance gene under the control o f  SV40 
promoter between the Murine Leukemia Virus Long 
Terminal Repeats (Morgenstern and Land, 1990). All p53 
cDNA-s were cloned between Xbal and В g ill sites of 
eukaryotic expression vector pCG (Tanaka and Herr,
1990). pCG-Hwt, pCG-Hisl75, pCG-Alal43 and pCG- 
Trp248 contain human wt, 175 Arg-*His, 143 Val-+Ala 
and 248 Arg-»Trp point mutation p53 cDNAs, respec­
tively. For creating pCG -A324-355, two regions o f wt p53 
cDNA were amplified: one between codons 1 and 323 and 
another between codons 356 and 393. Resulting cDNA-s 
were linked in frame to each other from P stl site designed 
into PCR primers. Half o f  P stl site (CAG) encodes an 
extra amino acid (Glu) between these two regions. This 
cDNA was inserted between Xbal and BgfLl sites of pCG 
vector and encodes p53 protein with amino acids 324-355  
deleted. AN39Trp encodes p53 protein with deletion o f the 
first 39 amino acids and 248 Arg-+Trp mutation. 
ДСЗб2Тгр encodes truncated protein with stop codon at 
position 362 and 248 Arg-»Trp mutation. 40-36 ITrp 
encodes mutant p53 starting from amino add 40, contain­
ing a stop codon at the position 362 and amino acid 
substitution at position 248. Schematic presentation of p53 
proteins is shown on Figure 1. Empty pCG does not 
contain any insert -  the poly (A) signal follows directly 
the CMV promoter.
p53 was detected with monoclonal antibodies pAb421 
(Harlow et a l, 1981, epitope between amino acids 372-381), 
pAblSOl (Banks et a l ,  1986, epitope between amino acids 
46-55), pAb240 (Gannon et a l ,  1990, epitope between 
amino acids 210-214) and B17 (Legros et a l ,  1994, epitope 
between amino acids 16-25). The last was generous gift from 
Dr. Thierry Soussi.
Cell culture and transfection
Saos2 cells were cultured in Iscove’s modified Eagle’s 
medium (IMEM) supplemented with 10% foetal calf 
serum. Cells were maintained at 37“C in humidified 5% 
C 0 2 atmosphere. Cells were transfected by electroporation
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method as follows: 5 -1 0  million cells were collectcd from 
70% confluent ccll dishes and suspended in IMEM 
containing 5 mM Na-BES (N,N-bis[2-Hydroxyethyl]-2- 
aminoethanesulfonic acid). SO /ig sonicated salmon sperm 
DNA, expression and reporter plasmids were added to 
250 1^ of cell suspension and the cells were transfected 
using ‘Invitogene’ electroporator (settings 1000 /jF and 
210 V). After electroporation, cells were resuspended in 
IMEM and transferred to growth conditions on 6 or 10 cm 
diameter cell culture dishes.
С A T and ß-galactosidase assay
1.2 ^g o f pBS-CON-CAT or pWWP-CAT and 0.5 fig o f 
pON 260 reporter plasmids were used per transfection. 
Cells were collected 24 h after transfection and lysed by 
three cycles o f rapid freezing and thawing. All lysates were 
normalised before CAT and /?-galactosidase reaction 
according to total amount o f protein (Bradford, 1976). 
Enzyme reactions were performed at standard conditions 
(Sambrook et al., 1989). For CAT assay thin layer 
chromatography plates were exposed to Phosphorlmager 
and data were quantitated with ImageQuaNT software.
Western blotting and oligomerisation assay
For Western blotting cells were lysed 24 h after transfec­
tion in 30 /il IP buffer (500 mM NaCl, 50 mM Tris-HCl 
pH 8.0, 5 mM EDTA, 1% NP-40, 0.02% N aN „ aprotinin 
mTIU/ml, 0.1 mM PMSF) for 30 min in ice. Cell debris 
were removed by centrifugation at 12 000 r.p.m. for 5 min, 
30 fi\ SDS loading buffer (50 mM Tris-HCl pH 6.8; 100 mM 
DTT; 2% SDS; 0.1% bromophenol blue; 10% glycerol) 
was added to lysate and it  was boiled for 10 min. Lysate 
w as separated by S D S-P A G E  in 12% gel. Proteins were 
transferred to nitrocellulose filter. Free surface o f the filter 
was blocked for 10 min at room temperature (RT) with 1 Vo 
non-fat milk powder in PBS+ 0.05% Tween 20. Filter was 
incubated with monoclonal antibody pAb240 in blocking 
solution for 2 h at RT. After washing with PBS + Tween 20 
filter was incubated for 2 h at RT with goat antibody 
against mouse Ig conjugated with alkaline phosphatase.
For oligomerization assay cells were transfected with 2 ßg 
of expression plasmid and lysed 24 h later in 150 ц\ IP buffer
on ice for 30 min. Each lysate was divided between five tubes 
and glutaraldehyde was added to final concentration of 0; 
0.003; 0.01; 0.03 or 0.1%. After incubation for 15 min on ice, 
equal volumes o f 2 x SDS loading buffer were added. Samples 
were boiled for 10 min, separated in 6% SDS-polyacrylamide 
gel and transferred to nitrocellulose filter. p53 was detected 
with antibodies рАЫ801, рАЬ421, pAb240 and rabbit anti­
mouse Ig secondary antibody conjugated with alkaline 
phosphatase (‘LabAs’, Estonia).
Immunofluoresence
Cells, growing on cover slips, were fixed at — 20°C in 
acetone/methanol (1:1). Primary antibodies were diluted in 
1% BSA in PBS and incubated at RT for 1 h. After 
washing three times with PBS cover slips were incubated 
with goat anti-mouse antibody conjugated with FITC 
(LabAs). Cells were visualised and photographed using 
Olympus AH-2 microscope.
Cell growth suppression assay
Saos-2 cells were transfected with pBabe Puro, pCG- 
Д 324-355 and with indicated plasmids (Figure 8). 
Twenty-four hours after transfection the cells were 
replated with equal densities (1.5 x 105 cells per 100 mm 
plate). Forty-eight hours after transfection the fresh 
medium containing puromycin (1 /jg/ml) was added. Cells 
were grown in the presence o f  puromycin for 1 week and 
then 1 week without the selection. After that cells were 
fixed in 0.05 glutaraldehyde in PBS, stained with 
Coomassie R-250, and the colonies were counted.
A ck n ow led gem en ts
We thank Dr Thierry Soussi for antibodies, Dr Bert 
Vogelstein for pWWP-CAT plasmid and for Trp248 
cDNA, Dr Juhan Sedman and Dr Tanel Tenson for 
critical reading o f the manuscript and Ilvi Rimm for 
excellent technical assistance. This work was partly 
supported by grant CT94002 from European Commission 
and grants from Estonian Science Foundation (no. 2315 
and 2316).
References
Balagurumoorthy P, Sakamoto H, Lewis MS, Zambrano N, 
Clore GM, Gronenborn AM, Appella E and Harrington 
RE. (1995). Proc. Natl. Acad. Sei. USA, 92, 8591-8595. 
Banks L, Matlashewski G and Crawford L. (1986). Eur. J.
Biochem., 159, 529-534.
Barak Y, Juven T, Haffner R and Oren M. (1993). EMBO J., 
1 2 ,4 6 1 -4 6 8 .
Baudier J, Delphin С, Grunwald D, Khochbin S and 
Lawrence JJ. (1992), Proc. Natl. Acad. Sei. USA. 89, 
11627-11631.
Bradford MM. (1976). Analytical Biochem., 72, 248-254. 
Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, 
Faha B, Seizinger BR and Kley N. (1995). Nature, 377, 
646-649.
Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, 
Sakamoto H, Appella E and Gronenborn AM. (1994). 
Science, 265, 386-391.
Cox LS, Hupp T, Mideley CA and Lane DP. (1995). EMBO 
J., 14, 2099-2105.
Crook T, Marston NJ, Sara EA and Vousden KH. (1994).
Cell. 79, 817 -827 .
El-Deiry W, Kern SE, Pietenpol JA, Kinzler KW and 
Vogelstein В. (1992). Nature Genetics, 1, 4 5 -4 9 .
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons 
R, Trent JM, Lin D, Mercer WE, Kinzler KW and 
Voeelstein B. (1993). Cell, 75, 817-825 .
Funk WD, Pak DT, Karas RH, Wright WE and Shay JW.
(1992). Mol. Cell. Biol., 12, 2866-2871.
Gannon JV, Greaves R, Iggo R and Lane DP. (1990). EMBO 
J., 9, 1595-1602.
Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, 
Chumakov PM and Gudkov AV. (1998). Nature, 391, 
295-298.
Goga A, Liu X, Hambuch TM, Senechal К, Major E, Berk 
AJ, Witte ON and Sawyers CL. (1995). Oncogene. 11, 
791 -799 .
Harlow E, Crawford LV, Pim DC and Williamson NM.
(1981). J. Virol.. 39, 861-869 .
Hupp TR, Meek DW, Midgley CA and Lane DP. (1992).
Cell. 7 1 ,8 7 5 -8 8 6 .
Hupp TR, Sparks A and Lane DP. (1995). Cell. 83, 237 -  245. 
Jayaraman L, Murthy KGK, Zhu C, Curran T, Xanthou­
dakis S and Prives C. (1997). Genes Dev.. 11, 558-570. 
Jayaraman L, Moorthy NC, Mutrhy KGK, Manley JL, 
Bustin M and Prives C. (1998). Genes Dev., 12, 462-472.
21
Mutants of p53 can inhibit Its monomeric form
A Jöers et al
Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, 
Walsh WV, Plunkett BS, Vogelstein В and Fornace AJ Jr.
(1992). Cell, 71, 587-597 .
Kern SE, Pielenpol JA, Thiagalingam S, Seymour A, Kinzler 
KW and Vogelstein В. (1992). Science, 256, 827-830. 
Knippschild U , Milne D , Campbell L and Meek D. (1996).
Oncogene. 13, 1387-1393.
Lees-Miller SP, Sakaeuchi K, Ullrich SJ, Appella E and 
Anderson CW. (1992). Mol. Cell. Biol., 12, 5041-5049. 
Legros Y, Lafon С and Soussi Т. (1994). Oncogene, 9,2071 -  
2076.
Levine AJ, M omand J and Finlay CA. (1991). Nature, 351, 
453-456 .
Liu X, Miller CW, Koeffler PH and Berk AJ. (1993). Mol.
Cell. Biol., 13, 3291-3300.
Lu H and Levine AJ. (1995). Proc. Natl. Acad. Sei. USA, 92, 
5154-5158.
Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T.
(1993). Nature, 362, 847-849.
Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ 
3d, Hill DE and Haber. (1993). Proc. Natl. Acad. Sei. 
USA, 90, 5100-5104 .
Maheswaran S, Englert C, Bennett P, Heinrich G and Haber 
DA. (1995). Genes Dev., 9, 2143-2156.
Martin DW, M unoz RM, Subler MA and Deb S. (1993). J.
Biol. Chem., 268, 13062-13067.
Mayr GA, Reed M, Wang P, Wang Y, Schweds JF and 
Tegtmeyer P. (1995). Cancer Res., 55, 2410-2417.
Meek DW, Simon S, Kikkawa U and Eckhart W. (1990).
EMBO J., 9, 3253-3260 .
Milne DM, Palmer RH, Campbell DG  and Meek DW.
(1992). Oncogene, 7, 1361 -  1369.
Milner J and M edcalf EA. (1991). Cell, 65, 765-774. 
Miyashita T and Reed JC. (1995). Cell, 80, 293-299. 
Morgenstern JP and Land H. (1990). NAR, 18, 3587-3596. 
Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F 
and Deppert W. (1995). EMBO J.. 14, 4442-4449.
Ouchi T, Monteiro A NA, August A, Aaronson SA and 
Hanafusa H. (1998). Proc. Natl. Acad. Sei. USA. 95, 
2302-2306.
Pellegata NS, Cajot JF and Stanbridge EJ. (1995). Oncogene,
11, 337-349 .
Sambrook J, Fritsch EF and Maniatis T. (1989). Molecular 
cloning: a laboratory manual, 2nd Ed., Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY.
Sang BC, Chen JY, Minna J and Barbosa MS. (1994).
Oncogcnc, 9, 853-859 .
Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, 
Weinmann R, Levine AJ and Shenk T. (1992). Proc. Natl. 
Acad. Sei. USA. 89, 12028-12032.
Shaulian E, Zauberman A, Milner J, Davies EA and Oren M.
(1993). EMBO J.. 12, 2789-2797.
Spaele RR and Mocarski ES. (1985). J. Virol., 56, 135- 143. 
Subler MA, Martin DW and Deb S. (1994). Oncogene, 9, 
1351 -1359.
Takenaka I, Morin F, Seizinger BR and Kley N. (1995). J.
Biol. Chem., 270, 5405-5411.
Tanaka M and Herr W. (1990). Cell, 60, 375-386.
Tarunina M and Jenkins JR. (1993). Oncogene, 8, 3165- 
3173.
Thomas M, Matlashewski G, Pim D  and Banks L. (1996).
Oncogene, 13, 265-273 .
Thut CJ, Chen JL, Klemm R and Tjian R. (1995). Science, 
267, 100-104.
Truant R, Xiao H, Ingles CJ and Greenblatt J. (1993). J.
Biol. Chem., 268, 2284-2287.
Wang P, Reed M, Wang Y, Mayr G, Stenger JE, Anderson 
ME, Sclnvedes JF and Tegtmeyer P. (1994). Mol. Cell. 
Biol.. 14, 5182-5191.
Wang Y, Reed M, Wang P, Stenger JE, Mayr G, Anderson 
ME, Schwedes JF and Tegtmeyer P. (1993). Genes Dev., 7, 
2575-2586.
Wang Y and Prives C. (1995). Nature. 376, 8 8 -91 . 
Wolkowicz R, Eikind NB, Ronen D  and Rotier V. (1995).
Oncogene, 10, 1167-1174.
Xiao H, Pearson A, Coulombe B, Truant R, Zhang S, Regier 
JL, Triezenberg SJ, Reinberg D, Flores O, Ingles CJ and 
Greenblatt J. (1994). M ol. Cell. Biol., 14, 7013-7024. 
Yuan ZM, Huang Y, Whang Y, Sawyers C, Weichselbaum 
R, Kharbanda S and Kufe D. (1996). Nature, 382, 272 - 
274.
Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi
D, Weber BL and El-Deiry WS. (1998). Oncogene, 16, 
1713-1721.
CURRICULUM VITAE
ARNOLD KRISTJUHAN
Date and place of birth: November 28, 1969, Rakvere, Estonia 
Marital status: married, two children 
Address: Institute of Molecular and Cell Biology,
Tartu University, Riia 23, Tartu, Estonia 
Address at home: Muru 10-20, Tartu, Estonia 
E-mail: akristj@ebc.ee
Education
1977-1988 Secondary School No. 3, Tallinn
1988-1992 Tartu University, Faculty of Biology and Geography, graduated as 
biochemist
1992-1994 M. Sc. student at Tartu University, graduated as M. Sc. in molecu­
lar biology.
1994-1998 Ph. D. student at Tartu University
Scientific work
Since 19901 have studied biological activities of tumour suppressor protein p53 
in group leaded by Prof. Toivo Maimets. Experimental part of this thesis is 
based on studies of transcriptional activator properties of p53.
83
CURRICULUM VITAE
ARNOLD KRISTJUHAN
Sünniaeg ja koht: 28. november 1969, Rakvere linn 
Perekonnaseis: Abielus, kaks last 
Aadress tööl: Molekulaar-ja Rakubioloogia Instituut, 
Tartu Ülikool, Riia 23, Tartu 
Aadress kodus: Muru 10-20, Tartu 
E-mail: akristj@ebc.ee
Haridus ja teenistuskäik
1977-1988 Tallinna 3. Keskkool
1988-1992 Tartu Ülikool, lõpetanud bioloogi-biokeemikuna 
1992-1994 Tartu Ülikooli magistriõpe, lõpetanud teadusmagistri kraadiga 
molekulaarbioloogia erialal 
1994-1998 Tartu Ülikool, doktoriõpe
Teadustegevus
1990. aastal liitusin dr. Toivo Maimetsa juhitava teadusgrupiga, mille uurimis­
teemaks on olnud kasvajate supressorgeeni p53 molekulaarsete toimemehha­
nismide uurimine.
84
DISSERTATIONES BIOLOGICAE 
UNIVERSITATIS TARTUENSIS
1. Toivo Maimets. Studies of human oncoprotein p53. Tartu, 1991, 96 p.
2. Enn K. Seppet. Thyroid state control over energy metabolism, ion transport 
and contractile functions in rat heart. Tartu, 1991, 135 p.
3. Kristjan Zobel. Epifüütsete makrosamblike väärtus õhu saastuse indikaa­
toritena Hamar-Dobani boreaalsetes mägimetsades. Tartu, 1992,131 lk.
4. Andres Mäe. Conjugal mobilization of catabolic plasmids by transposable ele­
ments in helper plasmids. Tartu, 1992, 91 p.
5. Maia Kivisaar. Studies on phenol degradation genes of Pseudomonas sp. 
strain EST 1001. Tartu, 1992, 61 p.
6. Allan Nurk. Nucleotide sequences of phenol degradative genes from Pseudo­
monas sp. strain EST 1001 and their transcriptional activation in Pseudomonas 
putida. Tartu, 1992, 72 p.
7. Ülo Tamm. The genus Populus L. in Estonia: variation of the species biology 
and introduction. Tartu, 1993, 91 p.
8. Jaanus Remme. Studies on the peptidyltransferase centre of the E.coli ribo­
some. Tartu, 1993, 68 p.
9. Ülo Langel. Galanin and galanin antagonists. Tartu, 1993, 97 p.
10. Arvo Käärd. The development of an automatic online dynamic fluorescense- 
based pH-dependent fiber optic penicillin flowthrought biosensor for the 
control of the benzylpenicillin hydrolysis. Tartu, 1993, 117 p.
11. Lilian Järvekülg. Antigenic analysis and development of sensitive immu­
noassay for potato viruses. Tartu, 1993,147 p.
12. Jaak Palumets. Analysis of phytomass partition in Norway spruce. Tartu, 
1993,47 p.
13. Arne Sellin. Variation in hydraulic architecture of Picea abies (L.) Karst, trees 
grown under different enviromental conditions. Tartu, 1994, 119 p.
13. Mati Reeben. Regulation of light neurofilament gene expression. Tartu, 1994, 
108 p.
14. Urmas Tartes. Respiration rhytms in insects. Tartu, 1995, 109 p.
15. Ülo Puurand. The complete nucleotide sequence and infections in vitro tran­
scripts from cloned cDNA of a potato A potyvirus. Tartu, 1995, 96 p.
16. Peeter Hõrak. Pathways of selection in avian reproduction: a functional 
framework and its application in the population study of the great tit (Parus 
major). Tartu, 1995. 118 p.
17. Erkki Truve. Studies on specific and broad spectrum virus resistance in trans­
genic plants. Tartu, 1996. 158 p.
18. Illar Pata. Cloning and characterization of human and mouse ribosomal protein 
S6-encoding genes. Tartu, 1996. 60 p.
2 2
19. Ülo Niinemets. Importance of structural features of leaves and canopy in deter­
mining species shade-tolerance in temperature deciduous woody taxa. Tartu, 
1996.150 p.
20. Ants Kurg. Bovine leukemia virus: molecular studies on the packaging region 
and DNA diagnostics in cattle. Tartu, 1996. 104 p.
21. Ene Ustav. E2 as the modulator of the BPV1 DNA replication. Tartu 1996. 100 p.
22. Aksel Soosaar. Role of helix-loop-helix and nuclear hormone receptor tran­
scription factors in neurogenesis. Tartu, 1996. 109 p.
23. Maido Remm. Human papillomavirus type 18: replication, transformation and 
gene expression. Tartu, 1997. 117 p.
24. Tiiu Kull. Population dynamics in Cypripedium calceolus L. Tartu, 1997. 124 p.
25. Kalle Olli. Evolutionary life-strategies of autotrophic planktonic micro­
organisms in the Baltic Sea. Tartu, 1997. 180 p.
26. Meelis Pärtel. Species diversity and community dynamics in calcareous grass­
land communities in Western Estonia. Tartu, 1997. 124 p.
27. Malle Leht. The Genus Potentilla L. in Estonia, Latvia and Lithuania: dis­
tribution, morphology and taxonomy. Tartu, 1997. 186 p.
28. Tanel Tenson. Ribosomes, peptides and antibiotic resistance. Tartu, 1997. 80 p.
29. Arvo Tuvikene, assessment of inland water pollution using biomarker respon­
ses in fish in vivo and in vitro. Tartu, 1997. 160 p.
30. Urmas Saarma. Tuning ribosomal elongation cycle by mutagenesis of 23S 
rRNA. Tartu, 1997. 134 p.
31. Henn Ojaveer. Composition and dynamics of fish stocks in the gulf of Riga 
ecosystem. Tartu, 1997. 138 p.
32. Lembi Lõugas. Post-glacial development of vertebrate fauna in Estonian water 
bodies. Tartu, 1997. 138 p.
33. Margus Pooga. Cell penetrating peptide, transportan, and its predecessors, 
galanin-based chimeric peptides. Tartu, 1998. 110 p.
34. Andres Saag. Evolutionary relationships in some cetrarioid genera (Lichenized 
Ascomycota). Tartu, 1998.196 p.
35. Aivar Liiv. Ribosomal large subunit assembly in vivo. Tartu, 1998. 158 p.
36. Tatjana Oja. Isoenzyme diversity and phylogenetic affinities among the eura- 
sian annual bromes (Bromus L., Poaceae). Tartu, 1998. 92 p.
37. Mari Moora. The influence of arbuscular mycorrhizal (AM) symbiosis on the 
competition and coexistence of calcareous crassland plant species. Tartu, 1998. 
78 p.
38. Olavi Kurina. Fungus gnats in Estonia (Diptera: Bolitophilidae, Keroplatidae, 
Macroceridae, Ditomyiidae, Diadocidiidae, Mycetophilidae). Tartu, 1998. 
200 p.
39. Andrus Tasa. Biological leaching of shales: black shale and oil shale. Tartu, 
1998.98 p.
ISSN 1024-6479 
ISBN 9985-56-353-0
